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The blood stage of the malarial parasite life-cycle is a vital stage that is believed to be a 
target for most antimalarial drugs. It is in this stage that host haemoglobin is degraded to 
provide nutrients for the survival of the parasite. However, a pathway (known as the haem 
detoxification pathway) that gives rise to the unique, microcrystalline ferriprotoporphryin IX 
[Fe(III)PPIX] dimer called haemozoin as an end-product, also arises as a result of the 
degradation. This haem detoxification pathway is a principal target for some of these 
antimalarials, especially those that contain the quinoline scaffold (e.g chloroquine), and has 
yielded outstanding results for the antimalarial drug discovery and development world. 
Even so, the spread of parasite resistance among these drugs has rendered most ineffective, 
resulting in a need for new scaffolds to target the pathway. However, the mode of action of 
chloroquine on haem may still be used as a model for identification of hits from these new 
scaffolds.  
The project entailed the synthesis of forty 4-substituted-1,4-dihydropyridine-3,5-
dicarboxylic ester derivatives (inclusive of 12 previously reported), as a new potential 
antimalarial chemotype. Syntheses were conducted using a Hantzsch pyridine reaction. 
Characterisation of these analogues was achieved using melting point, IR, 1H NMR and 13C 
NMR spectroscopy as well as HRMS. The compounds were tested against β-haematin 
formation as well as parasite growth, and from the data obtained, a structure-activity profile 
was deduced. At 95% confidence level, correlation analysis of the benzyl esters (29-38) 
revealed that antiplasmodium activity (decrease in logIC50) increases with a decrease in 
molecular weight (Mr) of the attached ester group and an increase in unsaturation (Fsp3) of 
the substituent. Small molecules with more unsaturated carbon bonds tend to be more 
drug-like because of their hydrophobic character which allows for membrane permeability 
and increased interaction with the hydrophobic haem macrocycle. The correlation yielded 
the empirical equation 
 Log IC50 = 0.0065Mr + 8.07Fsp
3- 4.78 
All the individual parameters were statistically significant at 95% confidence level. A single 
correlation for the alkyl esters revealed that increasing hydrophobicity increases the 
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parasite activity of the analogues (22-24, 26 and 28). The presence of the 1,4-
dihydropyridine (1,4-DHP) nucleus was essential to maintain both β-haematin inhibition and 
parasite growth-inhibition activities of the analogues. Thus, upon oxidation to a pyridine 
activity was lost. Comparison of the structural alterations performed on the 1,4-DHP 
molecule has permitted construction of a structure-activity model for its activity against the 
malarial parasite. For the 4-phenyl substituents, β-haematin activity was optimum when a 
large, electron-withdrawing, hydrophobic meta,para-disubstituted-4-phenyl-1,4-
dihydropyridine was attached. Hydrogen bond donating properties of the nitrogen atom in 
the dihydropyridine ring may be required to retain inhibition of β-haematin formation and 
the parasite in vitro. The presence of a basic N-heterocycle attached to the ester side chain, 
probably increases vacuolar accumulation but to the detriment of haemozoin inhibition. 
Attachment of larger alkyl groups on position 2 and 6 increase activity of the analogues.  
Three compound 25, 35 and 41 exhibited a nanomolar (nM) activity against the parasite in 
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1. Literature Review 
 
1.1 Introduction to Malaria 
The disease malaria has been and continues to be one of the most serious diseases to ever 
impact the human race, causing an intolerable burden on global human health and society. 
In 2013 alone, the disease affected more than 198 million people and led to 584 000 
deaths.1This disease, for which records date back as far as 2700 BC in Chinese history got its 
name from the Italian phrase “mal’aria’’ meaning ‘’spoiled air’’ (when ancient Romans 
discovered a disease regarded similar to malaria today).2, 3 It has been closely associated 
with swamps and dirty areas which are mostly found in developing countries (including 
Africa) where there is less or no infrastructure and the rate of poverty is high.4, 5 
Malaria is caused by parasitic protozoans from the Plasmodium genus and transmitted 
during the feeding process on human blood by the female Anopheles mosquito vector. 
Survival of the vector is greatly increased by warm, rainy climates found in tropical and sub-
tropical regions thus about 90% of malarial cases are found in these regions (Figure 1).5-9  
 
Figure 1:  Distribution of malarial transmission in 2013. 1 Adapted from reference 1. 
The fact that primary infection does not immediately induce immunity to the disease is the 
reason for predominance of the infection in young children under the age of five, who have 
no past exposure to the disease, as well as pregnant women. The symptoms include low 
birth weight (in pregnant women), severe anaemia, liver damage, coma and even death if 
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left untreated.  Development of partial immunity (pre-immunity), which is mainly seen in 
older people living in malarial endemic areas, results in an uncomplicated (or asymptomatic) 
malaria which exhibits mild symptoms similar to normal fever and has no or less severe 
effects. Immunity in the older population results in an unknown disease reservoir which 
becomes a pool spreading the disease. Figure 2 below shows age-specific clinical incidences 
and proportion of infection in high malaria endemic areas with an entomological inoculation 
rate of 85%.10-12 
 
Figure 2: Model demonstrating clinical incidences and infection prevalence according to the 
population age in high malaria endemic areas. 10 Reprinted from Clinical Microbiology and Infection, 
Vol 17, Gosling, R. D. Okell, L. Mosha, J. Chandramohan, D., The role of antimalarial treatment in the 
elimination of malaria, 1617-1623., Copyright (2011), with permission from Elsevier. 
 
Resistance to the cheapest and highly effective antimalarial drug chloroquine has increased 
the morbidity and mortality rate in the malarial regions, causing loss in economic growth 
thus increasing poverty .4,13 Therefore to ensure eradication of the disease in the next few 
decades, research and disease control need to be intensified. These include prevention of 
transmission from mosquito vector to the human host (including mosquito bed nets and 
insecticides), biologically understanding and control of the Anopheles vector (this reduces 
survival and breeding of the mosquito as well as yielding effective controls) and research on 
effective novel drugs and their mechanism of action. This project focuses on the latter. 
 
1.2 The Plasmodium Life Cycle and its biology 
There are five Plasmodium species (Plasmodium falciparum, Plasmodium ovale, Plasmodium 
vivax, Plasmodium malariae, and Plasmodium knowlesi) known to infect humans. All 
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undergo similar life-cycle and cause malarial disease. Owing to the ability of Plasmodium 
falciparum infected red blood cells (RBCs or erythrocytes) to avoid splenic clearance by 
adhering to endothelial cells that line the blood vessels in various body organs it can lead to 
obstruction of tissues. This causes severe complications making Plasmodium falciparum the 
most virulent among the Plasmodium species and a major cause of human deaths. This 
cytoadherance process of the infected RBC, which is caused by the parasite’s ability to re-
shape the infected cell forming knob-like spikes on the cell’s surface that assist in cell 
binding, is known as sequestration. It is mediated by Plasmodium falciparum erythrocyte 
membrane protein 1 (PfEMP 1) which is encoded by var genes. The var family is involved in 
clonal antigen variations which alter the parasite’s surface molecules giving it the ability to 
re-infect humans while evading the host’s acquired immune system, hence overriding the 
host’s defence system. 6, 7, 14-16 
 
The parasite’s complex life-cycle (Figure 3) alternates between the human vertebrate host 
and the mosquito vector, each with a dominating reproduction cycle.  
 
Figure 3:  The life-cycle of malarial parasite (Plasmodium species). 7Adapted by permission from 
Macmillan Publishers Ltd: [Nature] (reference 7), copyright (2002). 
 
The vertebrate cycle, which is the asexual stage, begins when an infected Anopheles 
mosquito feeds on human blood injecting parasitic sporozoites from its salivary gland 
together with an anticoagulant that assists in blood flow during the feeding process. The 
sporozoites enter through the human skin followed by movement through the bloodstream 
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to the liver where they invade the liver cells (hepatocytes) and undergo sequential asexual 
multiplication to form schizonts in a process known as pre-erythrocytic schizogony. This 
initiates the liver stage which lasts up to 25 days with no recognizable immunological 
pathogenic response. 2, 6, 7 
 
Within the hepatocytes the schizonts undergo mitotic division to enlarge and then mature 
to produce merozoites. These burst out of the hepatocytes into the bloodstream during liver 
schizont rupture. Following rupture they flow through the bloodstream and then invade 
passing RBCs initiating the blood stage (Figure 4). The infection now manifests as periodic 
headaches and fever that reoccur over a period of 48-72 hours depending on the 
Plasmodium species. It is this stage that serves as an important target to most known 
antimalarial drugs including quinolines (e.g chloroquine) and is clinically detected and 
formally named malaria. Within the RBC (erythrocyte) host haemoglobin is degraded inside 
the parasite food vacuole for nutrients, to maintain osmotic balance and to make space in 
the RBC in order to form larger trophozoites that replicate asexually into blood schizonts. 
These schizonts again form merozoites that are released during rupture of the infected RBC 
invading new RBCs and so repeating the cycle therefore increasing parasite population. 7, 17, 
18 
 
A minority of the merozoites form sexual female and male gametocytes that lie dormant in 
the blood stream until an Anopheles mosquito feeds on the infected host. During the 
feeding process the gametes are then transported to the digestive tract of the mosquito 
where sexual reproduction occurs. This results in formation of zygotes. Meiotic nuclear 
division of the zygote forms an oocyst, which undergoes mitotic division to form 
sporozoites. The new sporozoites are then transported to the salivary glands of the 
mosquito where they lie dormant until the next feeding, repeating the life-cycle of the 
parasite by infecting a healthy human being.6, 16, 18  
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Figure 4:  The blood stage of the Plasmodium life-cycle. The two fates for the merozoite, the 
formation of a trophozoite that completes the asexual cycle and the formation of gametocytes 
needed for the overall completion of the sexual stage of the malarial cycle.6 Reproduced from 
reference 6. 
 
1.3 The fate of haemoglobin  in the Plasmodium life cycle 
The ingestion of host haemoglobin by parasite trophozoites during the asexual blood stage 
is due to the parasite’s need of nutrients and space required for growth and completion of 
the life cycle as well maintenance of osmotic balance. Degradation occurs inside a lysosome-
like acid food vacuole (pH 4.8-5.2). The host haemoglobin is endocytosed from the RBC to 
this site. Within the food vacuole are proteolytic enzymes needed to degrade globin into 
peptides that are further degraded into amino acids by hydrolysis which occurs in the 
parasite cytoplasm.  
 
Even though the parasites digest 60-80 % of haemoglobin only 15% of the released amino 
acids are used in protein synthesis, while the rest is released into the circulation. Ferrous 
haem (ferroprotopophyrin IX, Fe(II)PPIX) is a by-product released during this digestion 
process. Haem is quickly and irreversibly oxidised to soluble ferric haematin (H2O/OH-
Fe(III)PPIX, the ligand is axial to the Fe(III) centre) by an unknown process thought to involve 
oxygen (O2) and generation of superoxide (O2
-). Large quantities of haematin are cytotoxic 
to the parasite and have been shown to cause lipid peroxidation and membrane 
destabilization also inhibiting various enzymatic processes. Thus the parasite has evolved a 
mechanism to detoxify this into an inert-microcrystalline form known as haemozoin.19-22 
Alternative detoxification mechanisms which include neutralisation of haem with histidine 
rich protein 2 peroxidative degradation of haem and reduced glutathione degradation,22-24 
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have been proposed, however, physico-chemical studies showed that about 95% of haem 
released from haemoglobin undergoes conversion to haemozoin. This detoxification 
pathway is specific to the Plasmodium parasite. 19-22, 25 Therefore inhibition of this pathway 




Figure 5: The pathway showing degradation of haemoglobin inside the Plasmodium infected red 
blood cell.  
 
1.4 Formation and Structure of Haemozoin 
The mechanism of haemozoin formation has been of contention in the literature, and while 
not fully understood, it has played a significant role in the discovery of the Plasmodium 
parasite and its life cycle as well as the role of the mosquito vector. Discovered years before 
the cause of malaria disease was known, scientific history shows that haemozoin played a 
major part in several breakthroughs in malaria research and antimalarial drug discovery.3, 26-
28 It is now strongly believed that formation of haemozoin in blood feeding organisms such 
as Plasmodium and the trematode worm Schistosoma mansoni is mediated by neutral lipids. 
The lipid mediated process was first described by Bendrat who suggested that polar lipids 
contaminating haemozoin extracts were the inducers of β-haematin formation. 20, 29, 30The 
hypothesis was later supported by Dorn et. al using acetonitrile extracts of trophozoite 
lysates. 31, 32 Further work was done by other groups including Pisciotta et.al using a sucrose 
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cushion centrifugation for isolation and thin layer chromatography as well as mass 
spectrometry for identification.20, 33-36 This demonstrated that these lipids existed as a 
mixture of monostearoylglycerol (MSG), monopalmitoylglycerol(MPG),  1,3-dioleoylglycerol 
(DOG), 1,3-dipalmitoylglycerol(DPG) and 1,3-dilineoylglycerol (DLG) in a 4:2:1:1:1 ratio in the 
form of neutral lipid nanospheres within the digestive vacuole (Figure 6). They further 
proposed that the role of these nanospheres was to protect the parasite from non-
enzymatic cleavage of haem which liberates the toxic peroxide molecule (H2O2) by enabling 
crystallisation of haem to haemozoin.19, 35, 37 
38  
Figure 6:  Transmission electron micrograph (TEM) of the asexual blood trophozoite stage. A early 
trophozoite with small haemozoin crystals and B mature stage with larger crystals (1 µm). C-E 
Scanning electron micrographs (SEMs) of haemozoin coated by the lipid. F-G show delipidated 
haemozoin crystals (100 nm). This figure was originally published in Biochemical Journal. J. M. 
Pisciotta, I. Coppens, A. K. Tripathi, P. F. Scholl, J. Shuman, S. Bajad, V. Shulaev and D. J. Sullivan, Jr., 
The role of neutral lipid nanospheres in Plasmodium falciparum haem crystallization. Biochemical 
Journal, 2007; 402: 197-204 © the Biochemical Society.  
Studies performed by Hoang et. al  and Ambele and Egan revealed that addition of neutral 
lipids (similar to the ones identified by Pisciotta et al) dissolved in acetone/methanol mixed 
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with haematin and layered onto an aqueous surface produced lipid droplets that efficiently 
mediated the formation of β-haematin (a dark-brown synthetic solid that is structurally and 
chemically identical to the biological haemozoin and first described by Hamsik in 1936.39 
Hoang et al. further proposed that the propionate group of ferriprotopophyrin IX extends 
towards the aqueous phase whilst the hydrophobic haem vinyl groups are embedded within 
the hydrophobic membrane layer at the interface of lipid and water. This alignment was 
proposed to facilitate β-haematin crystallisation.37, 40, 41  
Formation of haemozoin crystals involves dimerization of haematin (Fe(III)PPIX  Figure 7a) 
molecules with the propionate group of one Fe(III)PPIX molecule coordinating to the iron 
(Fe(III)) centre of another Fe(III)PPIX molecule. The two protoporphyrin rings interact by π-
stacking interactions with other dimers in the crystal. Extension of the dimer also involves a 
chain of hydrogen bonds between the propionic acid groups of neighbouring dimers. The 
crystals are centrosymmetric and have a thin narrow shape. The smallest face (c-face) is the 
fastest growing face of the crystal and believed to be the site where drugs bind. Figure 7b 
shows the structure of haemozoin.20, 38, 42  
 
Figure 7a: The Structure of heamatin excluding coordination of the H2O/OH
- ligand on Fe3+ centre.38 
Adapted by permission from Macmillan Publishers Ltd: [Nature] (reference 38), copyright (2000).  
 
Figure 7b: The crystal structure of haemozoin; blue dots illustrate hydrogen bonding between the 
two dimers.38 Made on the basis of CSD data of Pagola's structure . 
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1.5 Clinically used antimalarials and their mode of action. 
Malarial chemotherapy begins with an appropriate diagnosis of the type of Plasmodium 
species infecting the patient. Based on this, the disease is classified according to the level of 
severity and the drugs to be administered are selected.9, 12 The three major antimalarial 
drug classes that mainly target the asexual erythrocytic blood stage are classified according 
to their mechanism of action; these are the antifolates, antimitochondrial or the blood 
schizonticides. The latter are successful for being affordable, highly effective and safe, even 
though there is a lack of understanding about their mechanism of action.43, 44 
 
1.5.1 The antifolates 
The antifolates are known for interfering in the synthesis of folic acid and its biological 
pathway. This essential acid, functions as the co-factor involved in nucleic acid synthesis as 
well as for carrying one-carbon groups for methylation reactions and therefore limiting its 
synthesis inhibits parasite DNA synthesis (and amino acid metabolism through inhibition of 
methionine synthesis). This disrupts parasite growth and the successful completion of its life 
cycle. 
The class is further divided into two sub-classes as the type I and type II antifolates (Figure 
8). Type I which consists of pyrimethimine and proguanil (which metabolises to its active 
form cycloguanil once in the body) act on the schizont stage of the parasite asexual blood 
cycle and are dihydrofolate reductase-thymidylate synthase inhibitors. The enzyme 
dihydrofolate reductase-thymidylate synthase plays a bifunctional role in the synthesis of 
deoxythymidylate (responsible for parasite cellular DNA synthesis) and the regeneration of 
folic acid by catalysing the reduction of dihydrofolic acid to tetrahydrofolic acid using 
NADPH as an electron donor. Inhibition of the enzyme blocks the synthesis of nucleic acid 
precursors ultimately arresting cell division, growth and proliferation. 43, 45 The potency of 
the drugs is greatly enhanced when in synergetic combination with the sulfonamides such 
as sulfadoxine (type II antifolate class) that competitively inhibits dihydropteroate synthase, 
an enzyme responsible for folate biosynthesis. The combination is affordable and safe to use 
during pregnancy and was once also extensively used to combat chloroquine resistant 
malaria.44, 46 
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Figure 8:  The antifolate class of antimalarial drugs. 
The fact that most organisms, including human beings, use the folic acid-pathway as one of 
their key biosynthetic pathways requires specificity for the parasite enzymes in order to 
reduce adverse effects such as anaemia in humans. Owing to this, point mutations in genes 
encoding the two enzymes completely renders the drugs ineffective resulting in parasite 
resistance to them.47-50  
 
1.5.2 The antimichondrial drugs 
The malarial parasite mitochondrion is essential for various metabolic functions which 
include an electron transport system required for dispersement of electrons that assist in 
the reduction of dihydroorotate to orotate by dihydroorotate dehydrogenase during 
pyrimidine synthesis, a pathway essential for parasite DNA synthesis.51-53 This metabolic 
route is a target for the antimalarial drug atovaquone which selectively binds to the 
mitochondrion by interacting with ubiquinone-cytochrome c oxidoreductase (cytochrome 
bc1 complex or Coenzyme Q). This causes destabilisation, resulting in proton leakage within 
the complex and inhibition of the parasite mitochondrial electron transport system. The 
inhibition ultimately causes breakdown of the electro-potential of the mitochondrial 
membrane leading to oxygen consumption malfunctions and parasite death. The drug which 
is used in both chemoprophylaxis and treatment of mild (uncomplicated) malaria was 
initially administered as a monotherapeutic agent; however rapid occurrence of treatment 
failure (which is caused by its liphophilic character that leads to low aqueous solubility) as 
well as parasite resistance reduced its effectiveness.43, 51, 54, 55 In the pursuit of a reduced 
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treatment failure and drug resistance a fixed-ratio combination of atovaquone and 
progaunil, commercially known as Malarone® is now administered. Progaunil traditionally 
known for its antifolate activity (section 1.5.1) as a pro-drug to its metabolite cycloguanil 
acts by reducing the concentration of atovaquone required to inhibit the electron transport 
system, hence increasing the efficacy of the drug.51, 54, 56 Figure 9 displays the two combo-
therapeutics. 
                                              
Figure 9: The mitochondrial electron transport chain inhibitors. 
1.5.3 The blood schizonticides 
These drugs are believed to interact with haem and work by targeting the haem 
detoxification process occurring in the parasite food vacuole. They consist of synthetically 
derived artemisinin-containing drugs (a) and quinoline derived drugs (b), Figure 10. 
Chapter1: Literature Review 
12 | P a g e  
 
 
    
    
                                                                      
Figure 10:  The blood schizontocides; a the artemisinin-based drugs and b quinine and synthetic 
analogues (the quinoline drugs). 
1.5.3.1 The Artemisinin compounds 
The mechanism of action of this class of drugs is not well understood, however both haem 
and free iron have been suggested to activate the endoperoxide group of the drug causing 
cleavage of the bond leading to radicals that alkylate essential biomoleculecular 
components thereby killing the parasite. The drugs are known for their short half-life, but 
they are so effective and potent that they rapidly reduce parasitemia. Over the last decade 
an artemisinin-based combination therapy (ACT) has been used as the first-line standard 
a 
b 
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treatment against uncomplicated and chloroquine resistant malaria. This multi-drug 
combination treatment which administers arteminisin together with a long half-life drug 
(such as quinoline drugs amodiquine or mefloquine ) is believed to reduce the rate at which 
mutations confer resistance in endemic areas.43, 57-61 Even so the emergence of resistance 
towards artemisinin which involves the emergence of delayed-parasite clearance phenotype 
has been seen in countries such as Cambodia and Thailand.57, 62-64 
 
1.5.3.2 Quinine an ancient antimalarial 
The discovery of quinine, an ingredient found in the bark of the chichona tree which had 
been known to cure malaria since the 17th century, marks one of the greatest discoveries in 
the medical scientific world. Developed in the 1820s, quinine became a major 
chemotherapeutic for treating malarial associated fevers. However, owing to the drug’s 
toxicity and adverse effects to humans, less toxic and tolerable synthetic analogues (the 
quinoline-containing-compounds) such as chloroquine, piperaquine, amodiaquine, etc 
(Figure 10) were later discovered and used in preference to quinine.65, 66 The exceptional 
efficacy (prior to the emergence of resistance), affordability and safety of chloroquine made 
it the most clinically used antimalarial from the class.28, 67-69 Further discussion in this review 
illustrates the aspects of mode of action of the quinoline containing drugs and their 
structure activity relationships. 
 
1.5.3.3  The Mode of action of chloroquine and its structure activity relationships 
Although there has been advancement in the literature in understanding the mechanism by 
which chloroquine exerts its antimalarial potency, the exact mode of action is still not 
entirely understood. However, evidence supporting haem crystallisation as the target site of 
this drug has been the most widely accepted hypothesis (and the one with the strongest 
supporting evidence). In 2013, a publication by Combrinck et. al revealed that a chloroquine 
dose-dependent decrease of haemozoin together with a concomitant corresponding 
increase of cytotoxic haem correlated with parasite death (Figure 11). Other clinically used 
4-aminoquinolines such as amodiaquine (see structures in Figure 10) also caused an 
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increase in free haem in treated Plasmodium falciparum in cell culture.70 This study strongly 
supports the hypothesis that chloroquine is a haemozoin formation inhibitor.  
 
Figure 11: Dose-dependent plots of chloroquine treated parasites; left axis (open circle) parasite 
survival curve and percentage of haem as function of Log [chloroquine], right axis (closed circle).70 
Adapted with permission from reference 70. Copyright (2013) American Chemical Society 
 
Chloroquine is a weak base (pKa= 8.1 and pKa2= 10.2) and has a higher proportion of the 
neutral species at serum pH (pH= 7.4) and can therefore diffuse across cell membrane into 
the food vacuole (pH=4.8) where it is more extensively protonated and trapped inside. 
Thisresults in its accumulation (a term known as pH trapping) and the inhibition of 
haemozoin formation can occur. The importance of pH trapping for inhibition is seen in 
chloroquine-resistant parasites strains where there is a decrease in drug accumulation in the 
food vacuole (see 1.5.3.4).28, 43, 71, 72 
A detailed model of the structure-activity relationships in chloroquine with respect to 
haemozoin inhibition (or β-haematin since in vitro studies were performed) proposed by 
Egan et al revealed that β-haematin inhibition activity is a necessary, but not sufficient 
parameter for antiplasmodial activity. Moreover the amino side chain (which also assists in 
drug accumulation through pH trapping) is an essential requirement for strong 
antiplasmodial potency while the electron-withdrawing chloro group attached to the phenyl 
ring of quinoline assists in β-haematin inhibition. Interaction of the drug with haem occurs 
via noncovalent interactions that involve π-stacking interactions between the 4-
aminoquinoline and the Fe(III)PPIX porphyrin macrocycle, as well as hydrogen bonds and 
weak electrostatic interactions between the protonated ammonium group of the quinoline 
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and the propionoate groups of the haem.73 The proposed structure activity model is shown 
in Figure 12. 
 
Figure 12:  The proposed structure-activity relationships model of chloroquine essential for 
inhibition of the haem detoxification pathway. The model is based on a study performed on 19 
quinoline compounds.73 
 
Many years ago, the mechanism of haemozoin inhibition was thought to involve drugs 
binding to free haem in solution. However, more recently, evidence has pointed to the 
drugs inhibiting the crystal growth of haemozoin by docking onto the fastest growing crystal 
face of the haemozoin crystal, with intermolecular forces still playing an important role. 67, 
74, 75 
 
1.5.3.4  Chloroquine resistance 
Whilst the spread of resistance is related to the frequency at which mutations that confer 
resistance occur, processes such as the reduction in drug uptake and accessibility of the 
target, chemosentisation due to structural alterations, as well overexpression of the target 
site, also mediate drug resistance.76  
π-π stacking group. 
Weak bases: enhance 
drug accumulation via 





The alkyl side chain 
assist in antiplasmodial 
activity. 
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The emergence and spread of chloroquine resistant Plasmodium falciparum parasites has 
left an enormous challenge on the road towards the control and ultimate eradication of 
malaria. Chloroquine resistance, which originated in the late 1950s in Southeast Asia, is 
thought to be conferred by point mutations on the gene encoding for the Plasmodium 
falciparum chloroquine resistance transporter (PCRT), a protein embedded in the parasite 
digestive food vacuole membrane. Conferment of resistance is a result of amino acid 
substitutions at position 76 of PCRT, a region thought to be involved in substrate 
recognition. Replacement of the amino acid lysine by threonine (K76T) at this position leads 
to the electrochemical downhill efflux transportation of protonated chloroquine by PCRT. 
This efflux causes a reduction in drug accumulation and increases the IC50 (concentration at 
which a drug exhibits 50% inhibitory effects). Inhibition of the wild type (or sensitive) strain 
of parasites decreases their population while simultaneously increasing any resistant 
mutant parasite population, a term known as drug selection.28, 76-79 To circumvent 
resistance, structural alterations of 4-aminoquinolines have been performed in the 
literature by different groups. While some good results have been reported one also cannot 
ignore the toxicity of the quinoline scaffold possessed by these drugs (quinine as well as 
chloroquine). Some severe adverse effects (which include immune thrombocytopenia, 
hemolysis, blindness as well as death due to drug overdose) that led to quinine withdrawal 
have also been reported for chloroquine; hence a paradigm shift away from quinoline based 
antimalarial drug discovery has emerged.47, 73, 80 New drug candidates in this class should 
preferably be non-quinoline haem detoxification pathway inhibitors. 
 
1.6 Some approaches to drug discovery relevant to this project 
Understanding the mechanism of action of quinoline-based antimalarial drugs acting on the 
haem detoxification pathway is of great importance for the rational design of novel 
haemozoin inhibiting compounds. Drugs inhibiting this process require precise structure, 
shape and alignment of functional groups that will promote haemozoin (or possibly haem) 
binding in order for effective recognition and association to take place leading to inhibition 
of haemozoin formation. Furthermore, factors affecting properties such as lipophilicity and 
pH trapping are important in the context of recognition and cellular uptake of the potential 
drug.81, 82 While rational design of such inhibitors is not currently possible, an understanding 
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of the properties of chloroquine and its intermolecular interactions with haem (discussed in 
section 1.5.3.3) nonetheless has assisted in hit identification. 
In general, techniques such as high-throughput screening and computer-aided molecular 
modelling have been successfully used to identify potential hits (as well as their druggable 
targets) in order to quantify and further develop them into novel drugs via hit-to-lead 
beneficiation. The optimisation of physicochemical parameters of the hit compound results 
in the optimisation of interactions between substrate and the receptor (target) molecule 
leading to maximum activity, an approach underpinning the quantitative structure-activity 
relationships method. This method identifies properties related to the activity of the 
molecule using a series of analogues of the same scaffold.81, 83-86 Careful selection and 
evaluation of substitutional patterns performed on the template is essential for generating a 
meaningful set of rational design data as well as having implications for synthesis. One of 
the approaches often employed for this selection (also used for selection of some analogues 
synthesised in this study) is the Topliss decision tree method.87-89 The approach consists of a 
flow diagram which differentiates alkyl and phenyl substituents ultimately based on 
descriptors such as electrostatic effects, electron-withdrawing/releasing effects and 
lipophilicity of the compound as parameters describing the activity of the analogue. A 
compound is more potent (M), equivalent (E) or less potent (L) than the previous analogue 
and this forms the basis of selection of the next derivative for synthesis. In case of an 
increase in activity with increasing logP and minimal steric factor in alkyl side chains, the 
trend moves from the isopropyl to the benzyl and 2-ethylphenyl groups respectively. 
However where potency stays the same or is reduced, electronic effects also play a role. If 
the activity stays the same when moving from isopropyl to ethyl group, the pathway 
suggests more electron-withdrawing groups should be synthesised to improve the activity, 
while in a case of a reduction in potency further lead development must be undertaken. A 
similar rationale is applied for the aromatic substituents. Figure 13 demonstrates the Topliss 
pathways for alkyl side chains and aromatic substituents. This formed a basis on which 
diverse analogues were chosen, taking substituents from different branches of the tree 
(rather than sequentially progressing through the flow chart). 
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Figure 13: The Topliss scheme for a) The aliphatic side chains and b) the aromatic substituents.87, 88 
Reprinted with permission from (reference 87), copyright (1972), American Chemical Society. 
 
1.7 The 1,4-dihydropyridine (1,4-DHP) scaffold as an alternative antimalarial template 
A high-throughput screening study conducted by Vanderbilt University (Nashville, TN, USA) 
in collaboration with the University of Cape Town screened over 140000 compounds against 
parasite growth and haemozoin formation.90, 91 From this, a dihydropyridine compound 
(Figure 14) was found as the most active non-quinoline containing hit. 
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Figure 14: Structure of the dihydropyridine, hit molecule from high-throughput screening. 
 
The dihydropyridine scaffold has proven to be of remarkable pharmacological importance, 
notably providing the basis of L-type calcium-channel blockers that have been utilised in the 
treatment of cardiovascular diseases such as hypertension and exemplified by the 
commercial drugs nifedipine, amlodipine or nilvadipine, Figure 15. The drugs act as 
antagonists of the voltage-dependent calcium channel, disrupting calcium ion movement 
through the channel into cells. These ions are responsible for coupling signals that cause 
contraction of heart muscles (excitation state of the heart) thus inhibiting the channels that 
modulate heart rate which then prevents high blood pressure and chest pains. The scaffold 
has also provided the basis of other compounds with pharmacological activities such as 
antitumor, antituberculosis and antimicrobial agents. These molecules can also act as 
reducing agents of organic compounds by mimicking the NADH molecule shown in Figure 
16.92-94 This has drawn a lot of attention from medicinal chemists as well as evoking interest 
into the classical Hantzsch pyridine synthesis methodology which is a well-known way of 
synthesizing substituted pyridine derivatives via oxidation of the Hantzsch 1,4-
dihydropyridine products.95-97 
 
                            
Figure 15:  The L-type calcium channel blockers, 1,4-dihydropyridine drugs. 
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Figure 16:  The NADH molecule. 
 
This project involved the synthesis of analogues of the hit compound (Figure 14) in order to 
investigate structure-activity relationships necessary for inhibition of haemozoin  formation 
and ultimately parasiteviability. The synthesis used was based on the well documented 
Hantzsch pyridine synthesis mentioned above. Because the thiophene ring is similar in 
properties to benzene, it was decided to replace the thiophene at C-4 of the hit with a 
phenyl substituent. This was intended to provide more opportunity for exploring substituent 
changes since aromatic aldehydes are more readily available than substituted thiophene 2-
carboxaldehydes, Figure 17. 
 
Figure 17: Structure of the 1,4-DHP molecule used as the hit for analogue design. 
 
Previous work performed on the new aryl hit molecule had explored the effects of varying 
the 4-phenylsubstituents (X and Y) as part of developing structure-activity relationship 
profile of the template with respect to β-haematin inhibition (Mvumvu, BSc (Hons) project) 
(see Figure 17). Twelve 4-aryl-1,4-DHP analogues were synthesised using a microwave 
assisted Hantzsch pyridine reaction and their activity tested for β-haematin formation. 
Multiple correlation analysis performed on the anologues revealed a correlation at the 99 % 
confidence level between the logIC50 value with lipophilicity constant (π) and electronic 
constants, the resonance constant (R) and inductive constant (I) of X and Y. Based on the 
coefficient values found in the empirical equation, the substituent resonance effects had 
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slightly more influence than the inductive effects. Empirical equation (1.1) also shows a 
higher coefficient value for resonance constant than lipophilicity constant (π) denoting a 
greater weighting and hence influence on the activity. 
LogIC₅₀ = —0.498R—0.329π + 2.548  (r² = 0.79),     .........  equ (1.1) 
F = 12.93 > F₂,₇ = 9.55 
 
A two-tailed t-test on the individual parameters showed that both R and π significantly 
correlated with logIC₅₀ at the 95% confidence level (t = 2.74 (R), 4.22 (π) > tcrit = 1.90). The 
linear regression plot is shown in Figure 18. 
 
Figure 18:  The positive linear regression plot of predicted versus observed LogIC50 values for  
β-haematin inhibition for the 4-aryl-1,4-DHP analogues.98 
 
Observations from the equation show that the β-haematin inhibition activity increased with 
increasing lipophilicity of the C-4 substituent and increasing electron-deficient character. 
The maximum inhibition activity was seen with a hydrophobic C-4 phenyl disubstituted with 
electron-withdrawing groups at the meta and para positions. The trend in inhibition activity 
was supported by the Topliss decision tree. The best analogue was the 4-Cl-3-CF3-phenyl-
1,4-DHP (77 ± 17 µM) followed by 3,4-diCl-phenyl-1,4-DHP (115 ± 3.85 µM) as the second 
best. These results provided a starting point for the present study.98 
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At the beginning of the present project parasite testing on the series was performed and the 
results were rather disappointing. The initial thiophene hit compound together with its C-4 
phenyl derivative were synthesised at the University of Cape Town by Mr F. L’bbatte and Ms 
N. Mvumvu (Hons students in 2012) respectively and were both found to be inactive against 
parasite growth as well as β-haematin formation. QSAR studies revealed no correlation 
between the logIC₅₀ with any of the free energy parameters, although the 3,4-
dichlorophenyl-1,4-DHP (2.85 ± 0.03 µM) compound in Figure 19 was found to be the best 
analogue from the series and was therefore used as the hit for further development of this 
new antimalarial chemotype. 98 
 
Figure 19: The hit 4-phenyl-1,4-DHP analogue used for the project. 
 
This project thus investigated the synthesis of 1,4-DHP derivatives keeping the C-4 
substituent fixed as the optimised 3,4-dichlorophenyl group and performing different 
positional substitutions on the rest of the molecule. In this regard, a key objective was to 
vary the ester component of the molecule in order to establish the effect on β-haematin 
formation as well as parasite growth inhibition, see Figure 20.  
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Figure 20:  Structural alterations performed on the dihydropyridine template for the present project.  
 
β-haematin inhibition was measured using a commercially available detergent-based (NP-
40) 96-well plate assay that mimics the biological neutral lipid bodies formed in vivo in the 
parasite digestive food vacuole, while the in vitro antiplasmodial activity was measured 
against a chloroquine sensitive (NF54) strain and performed at the Pharmacology division, 
University of Cape Town Medical School.90, 99 
 
1.8 Rational analogue design 
1.8.1. Series 1: Variation of the ester groups. 
Most of the studies reported in the literature focus on variations made at the C-4 position of 
a dihydropyridine molecule whist keeping the ester group constant as either the readily 
available methyl (Me) or ethyl (Et) ester. This is presumably due to the commercial 
availability of simple acetoacetate Me and Et esters and their reliability in the Hantzsch 
reaction. Rarely has the ester component of the molecule been changed. This study focused 
on synthesising a series of dihydropyridine analogues as β-haematin inhibitors and as 
potential antimalarial agents based on varying the ester group. These variations focused 
into two ester sub-groups: a symmetrical template and unsymmetrical template, as shown 
in Figure 21. The symmetrical products contained either a) an alkyl or substituted benzyl 
group or b) an N-heterocycle attached to an alkyl tether. The unsymmetrical products 
contained simple alkyl groups (c in Figure 21). A range of commercially unavailable 
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acetoacetate esters prepared from methyl acetoacetate and commercially available 
alcohols, or synthesised alcohols 1-4 to produce compounds 5-20 (see chapter 2 for 
synthetic method and structures of the reagents) together with commercially available 
acetoacetate esters, these were required for the successful synthesis of the dihydropyridine 
analogues. 
 
Figure 21:  The 1,4-DHP ester analogues selected for the study. 
 
a) Variations containing alkyl and benzyl substituents  
Analogues selected were chosen with the aid of the Topliss decision tree, selecting groups 
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b) Analogues containing an N-heterocycle in the ester side chain 
In an attempt to increase vacuolar accumulation of the drug, two analogues with basic 
amine side chains were identified for the study. This was based on the mode of action 
hypothesised for chloroquine regarding the understanding that in the acidic vacuole weak 
bases become protonated and membrane impermeable, resulting in pH trapping.28, 73  
 
c) Effects on symmetry  
 Many of the known 1,4-dihydropyridine drugs, including the L-type calcium channel 
blockers, are unsymmetrical, and this sparked an interest into understanding the effect of 
chirality (or asymmetry) within the molecule on potential antimalarial activity. In this case 
the ester side groups were determined by the availability of reagents. 
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 1.8.2 Series 2: Variations in the C-2 and C-6 (R’’) groups 
Four analogues were chosen for understanding the influence of the C-2 group on activity; 




Figure 22: The analogues chosen for variation of the R’’ group. 
 
1.8.3 Series 3: The importance of the NH group on the dihydropyridine ring 
Hydrogen bonds provide the most crucial non-covalent interactions in biological systems 
and an important force in molecular recognition of receptors by their substrates or guest 
molecules (such as drugs). Intermolecular hydrogen bonds between Fe(III)PPIX dimers are 
an important feature of haemozoin and suggest that H-bonds may also be important for 
inhibition of haemozoin formation. The propionate side chains (on Fe(III)PPIX) that form the 
intermolecular bonds are proposed to be significant during interactions of haem with 
various proton donor moieties.67, 73, 75 The dihydropyridine molecule has one donor (the NH 
group in the ring) and three acceptor (the two carbonyl oxygens and the nitrogen in the 
ring) sites, respectively. Therefore, substitution of the hydrogen on the nitrogen ring would 
deny the possibility of hydrogen-bond donor character within the molecule. Hence a 
comparison of unsubstituted nitrogen (NH) with a substituted one needed to be 
undertaken. Figure 23 shows the variation identified. 
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Figure 23:  Analogues synthesised for evaluating H-bond donor influences on activity. 
 
1.8.4 Series 4: Pyridine analogues 
Studies performed by Schneider et al on the association energies of water-soluble porphyrin 
rings with small aromatic ring ligands revealed that increasing the number of π-electrons 
(thus increasing the aromatic rings) resulted in an increased strength of association.100 
Similar studies performed by Kuter et al also showed that the molecules with a greater 
number of conjugated π-electrons associated more strongly with haem.101 For this reason it 
was decided that investigation of the oxidised product (pyridine) of the dihydropyridine 
derivative would be interesting. Oxidation increases the number of π-electrons in the 
molecule as well as making the ring flat. Part of the work thus involved oxidizing some of the 
4-phenyl-1,4-dihydropyridine products synthesised previously at UCT, to their 
corresponding pyridine structures. This was aimed at investigating the effect on biological 
activity of changing from a non-planar, non-aromatic template to an aromatic and hence 
planar one, which it was hoped, would shed light on aspects of π-π stacking interactions 
with Fe (III) PPIX. Figure 24 shows the analogues chosen for the study.  
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Figure 24:  The oxidised derivatives selected for investigation.  
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1.9 Aim 
 The overall aim of the project was to develop a structure-activity profile for the 1,4-
dihydropyridine lead against β-haematin formation and malarial parasite growth. This 
required synthesising analogues of the new C-4 phenyl molecule (Figure 20) using the 
Hantzsch pyridine reaction.  
The study was designed to address the following aspects: 
(i)Variation of the ester component of the molecule (R and R’)  
(ii) The effects of symmetry on activity 
(iii) pH trapping and basicity of the compound.  
(iv) The importance of having the NH on the dihydropyridine ring 
(v) Extension of alkyl side chain of the R’’ group   
(vi) Oxidation of a dihydropyridine ring to a pyridine 
The synthesised compounds were characterised using 1H-NMR, 13C NMR and IR 
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2. Organic Synthesis 
2.1 An Overview and Mechanism of the Hantzsch pyridine reaction 
The remarkable Hantzsch pyridine reaction is a one-pot, three component reaction involving 
the reaction of an aldehyde, acetoacetate (usually ethyl acetoacetate) and ammonium 
acetate (as the source of ammonia) to yield a 1,4-dihydropyridine intermediate. This 
intermediate can then be subsequently oxidised to form the corresponding pyridine 
molecule, Scheme 1.  
Scheme 1: General scheme for the Hantzsch synthesis via a 1,4-dihydropyridine intermediate 
 
Formation of the 1,4-dihydropyridine intermediate involves the following steps: a 
Knoevenagel condensation between the aldehyde and the acetoacetate to form an enone 
intermediate, formation of an enamine intermediate from a second acetoacetate molecule, 
Michael addition of the enamine to the enone, tautomerism and cyclisation to afford the 
desired product. The Knoevenagel enone intermediate is formed via abstraction of an α-
methylene proton of the acetoacetate by the acetate ion as a base and the ammonium ion 
as an acid, followed by addition and elimination (E1cB mechanism) reactions. Proton 
abstraction is regio-selective because protons at this position are more acidic than those on 
the methyl ketone due to the presence of two strongly electron-withdrawing groups that 
stabilise the resultant conjugate base by resonance stabilization. Scheme 2 shows the 
mechanism of the Knoevenagel condensation step to form the enone. 
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Scheme 2:  The mechanism of the Knoevenagel step.102  
 
Ammonium acetate then condenses with the second equivalent of acetoacetate to form an 
enamine intermediate. The two intermediates then undergo Michael (conjugate) addition 
which is believed to be the rate-determining step, followed by cyclisation to form a 1,4-
dihydropyridine product. The removal of water from the reaction is the driving force for the 
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Scheme 3: An overview of the Hantzsch reaction.102 
 
2.2 Review of the synthesis of 1,4-dihydropyridine esters. 
A key objective in this project was to synthesize a library of Hantzsch 1,4-dihydropyridines 
varying the ester group while keeping the aldehyde component constant (see chapter 3), 
and for this a range of acetoacetate esters was required. Since most of the desired 
acetoacetate derivatives were unavailable commercially, methodology for their formation 
needed to bedeveloped. A number of methods for this are known in the literature and three 
of the main ones (including the one used in this project) will be described here as the 
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i) The Claisen condensation 
This is a carbon-carbon bond formation reaction involving an ester as the carbanion (instead 
of an aldehyde) in an aldol-type condensation. The enolate of the ester may be formed 
using a range of bases including the conjugate corresponding to the ester group (for simple 
self-condensations), and once formed undergoes a SNAc reaction with another molecule of 
undeprotonated ester to form the acetoacetate derivative. This is then stabilised by 
deprotonation in view of the enhanced acidity of the protons at the methylene group 
between the two carbonyl groups, ensuring that the product doesn’t undergo further 
Claisen reaction.  The reaction may involve different esters (cross-Claisen) in which case a 
strong, non-nucleophilic base needs to be used in order to avoid scrambling, Figure 25.102, 103  
 
 
Figure 25: A cross-Claisen condensation. 
 
Literature suggested that this methodology might be problematic for the range of 
acetoacetates required for this project.104 
 
ii) The diketene approach 
The acid- or base-catalysed addition of an alcohol to the four-membered lactone ring of 
diketene to yield a β-keto ester is a well-known reaction. The strained ring allows for 
nucleophilic attack of the alcohol on the carbonyl carbon resulting in ring opening of the 
molecule to afford the acetoacetate product. Figure 26 depicts the case for ethyl 
acetoacetate. A catalyst is required to enhance the poor nucleophilicity of the alcohol. 
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However, diketene is prone to hydrolysis and decarboxylation, and is quite toxic. Hence, this 
methodology was not seriously entertained either.103, 105, 106 
 
Figure 26: Addition of ethanol to diketene. 
iii) Transesterification 
The most efficient and straightforward approach for β-keto ester synthesis is via exchange 
of the ester group of a commercially available acetoacetate (methyl or ethyl) with an 
appropriate alcohol in a process termed transesterification. Such a process needs to be acid-
catalysed (Bronsted or Lewis) in which an acid is required to enhance carbonyl 
electrophilicity towards the poorly nucleophilic alcohol.103 Many catalysts have been used 
for this purpose such as zeolites, Lewis acids and bases, protic acids, solid acid, enzymes and 
transition-metal complexes. However, of these catalysts many are either expensive and / or, 
corrosive, or require synthesis.107-110  Ultimately, the approach selected was the one 
reported by Chavan in view of its simplicity and facile product isolation, in which zinc iodide 
(produced in situ from zinc dust and iodine) is used as a mild Lewis acid catalyst.111 
Mechanistically the exchange is proposed to proceed via complexation of the zinc iodide to 
both carbonyl groups resulting in a six-membered chelate, activating the ester for 
nucleophilic addition leading to exchange in view of the presence of a leaving group. 
Methanol is removed from the reaction via a Dean-Stark apparatus, which drives the 
reaction equilibrium to the right.104 The zinc iodide hydrolyses on work-up and is removed 
into the aqueous layer. Scheme 4 depicts a plausible ester-exchange mechanism for the 
transesterification. 
Chapter 2: Organic Synthesis 
35 | P a g e  
 
 
Scheme 4: The proposed reaction mechanism for acetoacetate transesterification using zinc iodide 
as catalyst. 
2.3 Synthesis of the acetoacetate analogues  
The analogues were selected in alignment with rational design aspects of the project, which 
were described in Chapter 1 (section 1.8, Topliss tree approach). The transesterification 
method used  2.0 mole equivalents of zinc, 1.2 mole equivalents of alcohol and 0.1 mole 
equivalents of iodine with respect to methyl acetoacetate in toluene at 110 °C and was 
applied to the synthesis of 6 (cyclohexyl) and 8 (benzyl) acetoacetate analogues, which were 
obtained in 80% and 85% yields respectively after work-up and chromatography. Owing to 
this success, the above conditions were applied to the other alcohols. Analogues 1-4 were 
prepared as pre-requisite substrates for further use in the reaction. Table 2 shows the 
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Table 2: Percentage yields for the acetoacetate derivatives. a) The benzyl analogues and b) The alkyl 
side chains. 
 
     
        
                                                             
     
 
Product 8 9 10 11 12 13 14 15 16 17
Y H o -Cl p -Cl m -Cl p -Br p -Me m -Me 3,4-Cl 2,4-Cl 3,4-Me
Yield 80 85 83 79 66 76 54 57 99 32
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Yields for the exchange ranged from modest ( 60%) to very good ( 80%) except for 
products 7, 17 and 18 where yields were disappointingly low (< 35%). Reasons for this were 
unclear although for analogue 18 it was hypothesised that the nitrogen atom in the pyridine 
ring co-ordinated with the catalyst forming a complex that competed with the six-
membered chelate, Figure 27. In search of conditions that would overcome the competing 
complexation in the case of 18 where the yield was unacceptably low (14 %), a series of 
reactions were performed at 110 °C changing the molar equivalents of methyl acetoacetate 
involved in the reaction. Table 3 shows how yield increased with increasing molar 
equivalents of methyl acetoacetate used. Ultimately, 5 mole equivalents of methyl 
acetoacetate with 1 mole equivalent of 2-(2-pyridyl)ethanol in the presence of 2 mole and 
0.1 mole equivalents of zinc dust and iodine respectively gave an acceptable yield of 70 % of 
the desired product. 
 
Figure 27:  The proposed pyridine-ZnI2 complex. 







Zinc (mmol) Iodine (mmol) Yield % 
1 1.2 2 0.1 14 
2 1 2 0.1 20 
5 1 2 0.1 69 
8 1 2 0.1 70 
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The NMR spectra of the acetoacetate products derived from the alkyl alcohols,revealed two 
core diagnostic singlets resulting from the ketone methyl group (H-1, range of 2.17-2.34 
ppm) and the deshielded methylene group (H-3, range 3.26-3.46 ppm) in the 1H spectra, 
together with two highly downfield carbonyl carbons and the signals for each ester R group 
in the 13C spectra. These data strongly supported the existence of the keto form as the 
dominant tautomer based on the observation of the H-3 methylene singlet. Similarly, the 13C 
NMR revealed four core resonances for carbonyl, methyl and methylene groups together 
with the relevant ester group signals. Figure 28 shows the 1H NMR and 13C NMR spectra of 6 
as a representative case. The 13C NMR spectrum suggests, possibly, that a small amount of 
enol is present by virtue of a peak at 90 ppm for the C-3 vinyl carbon. The existence of this 
tautomer might be due to its stabilisation by intramolecular hydrogen bonding, Figure 29.  
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Figure 28b:  The 13C NMR spectrum for 6. 
 
Figure 29: The diagram illustrating the keto-enol tautomerism for analogue 6. 
 
Another generic type in the project was based on using a substituted benzyl alcohol in the 
exchange. Here, in addition to the observed 1H NMR signals for the acetoacetate core, a 
singlet was always observed at approximetely 5.0 ppm corresponding to the benzyloxy 
methylene protons. The analogues showed variation only in the aromatic region due to the 
substituents. Likewise, additional core signals for methylene and aromatic carbons were 
observed in the 13C NMR spectra. The 1H NMR and 13C NMR spectra of analogue 8 
demonstrate a typical profile, Figure 30.  
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Figure 30a: The 1H NMR spectrum of 8 as the prototype for benzyl acetoacetate analogues. 
 
Figure 30b: 13C NMR spectrum for analogue 8. The expansion shows the aromatic carbons. 
2.4 The library of Hantzsch-ester 1,4-DHP analogues 
i) Synthesis and rationale: 
Although the library synthesis in this study utilized 3,4-dichlorobenzaldehyde as the 
aldehyde component throughout, earlier optimization studies had used 4-
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nitrobenzaldehyde with ethyl acetoacetate and ammonium acetate in ethanol. For the latter 
the best stoichiometry for optimal yield was found to be 5 mol equivalents of ammonium 
acetate with 20 mol equivalents of ethyl acetoacetate with respect to the aldehyde in 
ethanol at 60 °C using microwave irradiation. Figure 31 shows how the yield increased 
logarithmically with increasing mol equivalents of ethyl acetoacetate in the microwave 
reaction.98 Therefore, for the synthesis of the library of derivatives in this project using 3,4-
dichlorobenzaldehyde it was decided to use these same conditions on the basis that 
variation of thealdehyde should not have a significant effect. Fortunately, this turned out to 
be a valid assumption. 
 
Figure 31: A plot depicting the increase in % yield with increasing mol equivalents of acetoacetate 
for Hantzsch synthesis with 4-nitrobenzaldehyde and ethyl acetoacetate. 
Therefore, these one-pot, three-component, experimentally optimised Hantzsch reaction 
conditions were employed in the synthesis of the 1,4-DHP esters using the modified 
acetoacetate esters prepared. The reaction progress was monitored by TLC  (hexane/ ethyl 
acetate 3:1) every 3 minutes for microwave (to avoid over-irradiation leading to degradation 
and low yield) or each hour for reactions conducted at reflux under N2. Generally the 
reaction times ranged from 8 minutes to 26 minutes for the microwave and 2 hours to 
overnight for reactions conducted at reflux. Owing to unavailability of the microwave 
machine for a period of two months, conventional heatingat 80 °C was implemented for 
analogues (22, 24, 26, 27, 28 and 29) speculated to be prone to dehydrogenation. Owing to 
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formation of side products, after several attempts to synthesise the 1,4-DHP pyridine ester 
analogue from acetoacetate 18, the synthesis was deemed unsuccessful. Upon completion 
of the reaction, products were isolated by column chromatography to give yields, ranging 
from moderate to excellent (51-96%) with greater than 95% purity as determined by HPLC. 
The same conditions were used for the synthesis of ketone 21.Analogue Table 4 shows the 
results. 
Table 4:  The percentage yields for the 1,4-dihydropyridine ester series. * denotes ketone 
(Me) instead of ester (OR). 
 
 
Product R R' Yield % Product R R' Yield %
21 * Me 88 32 Me 97
22 Me 66 33 Me 89
23 Me 94 34 Me 96
24 Me 72 35 Me 83
25 Me 91 36 Me 73
26 Me 51 37 Me 62
27 Me 82 38 Me 62
28 Me 80 39 Me Et 93
29 Me 96 40 Et Et 98
30 Me 87 43 Me 62
31 Me 78 44 Me 83*Denotes ketone 
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Characterisation of the products by the usual range of spectroscopic techniques (NMR, IR 
spectroscopy and Mass Spectrometry) was divided into two groups as 1,4-dihydropyridines 
with alkyl esters and those with benzyl esters. 
1,4-dihydropyridines with alkyl esters (21-28 and 39-40): 
The 1H NMR spectra of the 1,4-dihydropyridines with alkyl esters differed only in the alkyl 
region due to the ester portion of the molecule, variation of which had little effect on the 
other signals. Variations in the substitution pattern in the alkyl region could also be 
discerned since either four signals were observed (for the isopropyl, ethyl and cyclopentyl 
analogues) or five signals for the more complicated allyl, t-butyl and cyclohexyl analogues. 
Each analogue revealed a core set of signals for the dihydropyridine moiety corresponding 
to: a singlet for H-4, a methyl singlet corresponding to the methyl groups at C-2 (for 
analogues 21-28), and three aromatic signals (originating from the lead aldehyde used in the 
reaction (3,4-dichlorobenzaldehyde)) integrating for three protons and splitting as two 
doublets and a doublet of doublets. The latter signal, corresponding to H6’, was due to 
coupling to H-5’ and H-2’ with typical ortho ( 8 Hz) and meta ( 2 Hz) coupling constants 
respectively. Similarly, the 13C NMR spectra revealed the core signals for the dihydropyridine 
and phenyl moieties: five quaternary carbon signals (C-2, C-3, C-1’, C-3’, C-4’), one for the 
carbonyl carbons, one for the carbon at position 4 and one for the methyl group (except for 
analogues 39 and 40, which had the C-2 methyl group replaced by an ethyl group). 
1H NMR spectrum for analogue 40 
The alkyl products contained mirror-plane symmetry and were thus achiral. However, 
products containing methylene groups bonded to the ester oxygen contained prochiral 
methylene carbons with diastereotopic hydrogens, which in some cases resulted in geminal 
coupling being observed between the two magnetically non-equivalent hydrogens. A case in 
point is the C-2 ethyl analogue 40 shown in Figure 32a in which the two methylene 
hydrogens appear as two independent doubled quartets due to geminal and vicinal 
coupling. The IR spectra generally displayed a broad NH peak at  3500 cm-1, a band at 1645 
cm-1 for the C=C aromatic stretch, a band at 1695 cm-1 for the C=O group and the C-H 
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alkene/ alkane peaks were observed at  3000 cm-1 and 2900 cm-1, respectively. 
Spectroscopic analysis of 40 is shown below in Figure 32, where ethyl propionylacetate was 
used as the acetoacetate. Interestingly, both methylene groups show diastereotopic 
geminal hydrogen nuclei. High resolution mass spectrometry (Figure 32d) also gave 
substantial evidence in support of 40. The high resolution mass spectrum shown in Figure 
32d gave the dominant ion as [M+H]+ with an observed molecular mass of 426.1243, which 
was within acceptable limits to the molecular mass expected of the [M + H]+ ion equal to 
426.1239. This ion contained two 35Cl isotopes, 35Cl being the major isotope.. The mass 
spectrum also showed the other dominant ion containing a combination of 35Cl and 37Cl 
isotopes, which appeared as a signal  at 428.1218 due to the masses of the two different Cl 
ions. Other minor combinations were also revealed. Derivative 40 was also revealed to be 
99 % pure by HPLC, Figure 32e. 
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Figure 32a: The 1H NMR of 40 in CDCl3. H-6’ couples to both H-5’ and H-2’ in the aromatic region. 
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Figure 32c: The IR spectrum for analogue 40. 
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Figure 32e: The high-performance liquid chromatograph of analogue 40. 
Analogues containing an N-heterocycle in the tether 43 and 44. 
For the purposes of investigating the effect of pH-trapping on activity, synthesis of 
analogues having a second amine group in the molecule in order to increase basicity 
(protonation in the food-vacuole which promotes inhibitor accumulation) was implemented. 
This came in the form of either a piperazine (43) or piperidine (44) in the alkyl side chain. 
Piperazine derivative 43 is used for illustration purposes. As before, the 1H NMR spectrum 
showed the presence of a diastereotopic quartet for the alkoxy methylene (OCH2) protons 
at  4.18 ppm. The methylene protons (NCH2) in the piperazine ring revealed two downfield 
triplets with a coupling of J= 6.0 Hz, with H-3” being the more deshielded by virtue of the 
electron-withdrawing Boc group, which resonated as expected as a singlet, Figure 33. 
Similarly, the 13C NMR spectrum of 43 showed the NCH2 singlets at 56.5 (NCH2CH2O), 53.7 
(H-3’’) and 43.6 (H-2’’) respectively. HRMS confirmed the structure (HRMS (EI): m/z 
766.3346 [M+H+], C37H54Cl2N5O8 requires 766.3349). 
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Figure 33a:  The 1H NMR of 43.  
 
Figure 33b:  The HRMS of 43.  
Synthesis of N-methylated 1,4-DHP ester 42: 
In order to address whether the NH group of the dihydropyridine moiety is essential for 
activity, we decided to mask this group with a simple methyl substituent. N-methylation of 
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23 was undertaken by taking advantage of the acidity of NH, which  forms part of a 
vinylogous amide and thus could be removed by a strong base (NaH at 0 °C; weaker bases 
like NaOH failed to promote methylation). Dimethyl sulfate was used as the methylating 
agent at 0 °C, which produced the desired N-methyl derivative in 98% yield after work-up 
and chromatography. A mechanism for the reaction is depicted in Scheme 5 showing the 
resonance stabilisation of the anion. A regioselective methylation on nitrogen ensures that 
conjugation is preserved.  
 
Scheme 5: The mechanistic scheme for the formation of 42. A dihydropyridine resonance hybrid for 
the anion is also shown. 
The spectra for the product were consistent with the proposed structure for 42 in that 
disappearance of the broad NH peak at  5.50 ppm and that at  3500 cm-1 in the 1H NMR 
and IR spectra respectively was observed. In addition, a new singlet for the newly 
introduced N-methyl group was observed at 3.18 ppm in the 1H NMR spectrum  confirming 
the introduction of an N-methyl group, Figure 34c. Purity of analogue was 97% 
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Figure 34:  The a) IR, b)1H NMR and c) the HPLC spectra for analogue 42. The * illustrates the 
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The 1,4-DHP benzyl esters (29-38) 
The 1,4-DHP benzyl esters differed from alkyl counterparts only in the aromatic region of 
the spectra due to the additional, substituted phenyl group of the ester side chain in each 
case. As with the alkyl analogues each benzyl analogue revealed the same core set of NMR 
signals (1H and 13C) as described previously. The 1H NMR spectra revealed an additional AB 
quartet for the diastereotopic benzyloxy methylene groups (OCH2) also as a diagnostic part 
of the core signals as well as the relevant aromatic signals, depending on the substitution 
patterns introduced onto the aromatic ring. In the 13C NMR spectra an additional core signal 
at 60.0 – 66.0 ppm  for the benzyloxy methylene group (OCH2) provided a marker for the 
successful synthesis of these analogues, and an additional four aromatic singlets were 
observed for the para-substituted analogues or six for the less symmetrical disubustituted 
rings. The 1H NMR and 13C NMR spectra for analogue 29 unsubstituted in the benzyloxy 
aromatic ring (X=H) in Figure 35 are shown to represent these features. Of note is the clear 
AB doublet pair for the diastereotopic benzyl hydrogens at around 5 ppm. The observed 
molecular mass of the dominant ion [M+H]+ was found to be 522.1241, which was within 
acceptable limits of the molecular mass expected for the [M+H]+ ion equal to 522.1239, 
Figure 35c. 
 
Figure 35a: The 1H NMR spectrum of 29 in CDCl3 as the prototype for the 1,4-DHP benzyl esters. 
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Figure 35b: The 13C NMR for 29.  
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The unsymmetrical 1,4-DHP ester 41 
The use of an acetoacetate derivative in the multicomponent Hantzsch reaction results in a 
symmetrical product only. Differentiating the two esters of the dihydropyridine molecule 
disrupts C-2 symmetry resulting in the creation of a chiral centre at the C-4 methine carbon 
as a racemic product, and the effect of desymmetrizing the ring on biological activity was 
considered to be an interesting part of the study. 
In order to access unsymmetrical derivatives two options were available. Either two 
different acetoacetates could be reacted (A and B, say), giving three different products as 
the two symmetrical derivatives (one from A and one from B) as well as the unsymmetrical 
derivative (A and B combined). Such a mixture would no doubt be difficult to separate into 
its components. Alternatively, one could do a targeted synthesis, which is more complicated 
but nevertheless is represented in the literature. Here, the two intermediates needed for 
the Michael addition would need to be synthesised in different flasks using each of the two 
acetoacetates, and thereafter condensed together to form the unsymmetrical product.96, 112, 
113 Ultimately, the latter option was adopted in which a mixture of tert-butyl acetoacetate, 
3,4-dichlorobenzaldehyde  and triethylamine (Et3N) in ethanol was microwave irradiated for 
a minute in order to yield the enone intermediate, which resulted in a change in reaction 
colour from colourless to yellow and was observed as a yellow smudge on the TLC that was 
different in Rf to those of the starting materials. The product was not isolated as it was 
thought likely that the Knoevenagel condensation would occur. As usual a commercially 
available enamine (ethyl-3-aminocrotonate) together with a few drops of glacial acetic acid 
was then added to the reaction in order for the two intermediates to undergo Michael 
addition. Completion of the reaction as monitored by TLC occurred after 15 minutes, and 
the product was obtained in 36% yield after column chromatography. A blue fluorescence 
under Uv/vis (250 nm) typical of 1,4-dihydropyridines was visible on TLC. Scheme 6 below 
shows the overall reaction. 
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Scheme 6:  The schematic diagram for the overall reaction for analogue 41. 
The asymmetric nature of the product now led to differences in the core signals in the NMR 
spectra compared to those of the symmetrical cases. Thus, the two methyl groups on the 
dihydropyridine ring appeared as two singlets rather than one in both 1H and 13C NMR 
spectra (2.32 ppm and 19.6 ppm for Me-6 as well as 2.30 ppm and 19.5 ppm for Me-2 
respectively). Likewise, the 13C NMR spectrum revealed the two ester carbonyl groups as 
different at 167 ppm (COt-butyl) and 166.5 ppm (COethyl). The identity of the peaks was 
resolved using HSQC and COSY NMR spectra. Figure 36 shows the 1H and 13C NMR spectra 
for 41. The molecule is now chiral (although racemic) but this cannot be ascertained directly 
from the NMR (NMR doesn’t distinguish enantiomers), and as before diastereotopic 
methylene hydrogens were observed for the ethyl ester fragment. 
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Figure 36a:  The 1H NMR for analogue 41.  
 
Figure 36b:  The 13C NMR spectra for analogue 41 * denotes the two methyl peaks.  
Literature has revealed that a symmetrical dihydropyridine is one of the products (by-
products) formed during the synthesis of an unsymmetrical dihydropyridine derived from 
preformed coupling partners (enone and enamine), themselves derived from different 
acetoacetate substrates.94, 96, 113 Studies have proposed this to be due to a retro-Michael 
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addition involving an iminium ion in equilibrium with the enamine intermediate. This was 
observed in the synthesis of unsymmetrical dihydropyridine 41 (3-tert-butyl-5-ethyl-4-(3,4-
dichlorophenyl))-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate), in which the 
symmetrical dihydropyridine derivative 23 was also formed as a major by-product in 30% 
yield. Scheme 7 shows the mechanism for these two reactions involving the same 
intermediate. 
Scheme 7: The two mechanisms illustrating the formation of unsymmetrical and symmetrical  
1,4-DHPs respectively during the modified Hantzsch synthesis of the unsymmetrical 1,4-DHP 41. 
2.5 Aromatization of the 1,4-DHP ring 
As stated in Chapter 1 previously, one of the aims was to investigate the effect on biological 
activity of oxidising the Hantzsch 1,4-dihydropyridine intermediate to its corresponding 
pyridine derivative. Derivatives A45-A48 were subjected to oxidation under heterogeneous 
conditions (chosen because of their experimental simplicity, their cost-effective, and 
environmentally safe nature as well as the availability of reagents). The reagent chosen, 
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developed by Zolfogol et al., involved using the inorganic oxidant oxone® (K2SO4. KHSO4. 
2KHSO5) in conjunction with sodium nitrite (NaNO2). The latter acts as a strong electron 
acceptor, and is adsorbed onto wet silica (SiO2 (50% w/w), which acts as a phase transfer 
catalyst and heterogeneous in situ surface area (for the generation of NOKSO5
-).114, 115 
Yields were moderately good (63-70%) the reactions proceeded relatively fast (1–2 hours), 
and the products could be separated easily by column chromatography, followed by 
recrystallisation to afford pure products. Table 5 illustrates the results.  




In addition, pyridine analogue 49 was inadvertently obtained under microwave conditions 
that were used during the target synthesis of Hantzsch analogue 29 (benzyl group) based on 
the disappearance of the NH and H-4 methine protons in the 1H NMR spectrum of 29 at 5.50 
ppm and 4.18 ppm. The cause of oxidation was not fully understood. The appearance of an  
N=C stretch at 1500 cm-1 together with the absence of the NH peak at  3500 cm-1 in the IR 
spectrum lent further support for the formation of the pyridine analogue. The appearance 
of three extra aromatic resonances for the pyridine ring in the 13C NMR spectrum (notably, 
C-3 of 29 shifted from the alkene region ( 103.0 ppm) into the aromatic region at 126.0 
Compound R X Yield%
45 Et 3,4-Cl 70
46 Et 4-Cl-3-CF₃ 66
47 Et 4-NO₂ 69
48 3,4-Cl 63
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ppm to give seven aromatic quaternary carbon signals in total, one for the benzyl phenyl) 
provided confirmation that oxidation to the pyridine had taken place, Figure 37.   
 
Figure 37a: The 1H NMR spectrum of 49 as the oxidised product of 29.*illustrates the position of the 
NH and H-4 peaks in the starting material. 
 
Figure 37b: The 13C NMR spectrum of 49 in CDCl3. Expanded insert spectrum showing the aromatic 
carbons including five of the seven quaternary carbon signals. 
OCH2 
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Figure 37c: The IR spectrum of 49 as an example of a pyridine analogue. * denotes the absence of 
the NH peak. 
 
Figure 37d:  The HPLC trace of analogue 49. 95% purity 
100015002000250030003500
C=O 
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Figure 37e: The high-res mass spectrum of 49. Expected m/z: [M+H]+ 520.1082, observed[M+H]+ 
520.1087    
 
In conclusion, the Hantzsch reaction was successfully used in the synthesis of a small library 
of 1,4-dihydropyridines containing novel ester side-chains. Microwave conditions gave the 
best results in which yields ranged from 51-98 % and in which a level of correlation between 
the type of ester and the yield could be identified. The acetoacetate esters were synthesized 
via transesterification of methyl acetoacetate with various alcohols using zinc iodide as 
catalyst. This expands on the type of ester grouping in the Hantzsch repertoire. The 
exception was in the synthesis of derivative 29 which oxidised to the pyridine 49, although 
the Hantzsch derivative 29 could be obtained using a conventional heating. Oxidation to the 
pyridine derivative, though also of interest for biological evaluation, could be achieved 
routinely using oxidation with oxone on silica-gel.  Following recrystallisation in triplicate, 
the Hantzsch products were analysed by HPLC and found to be >95% pure and thus of an 
acceptable purity for biological evaluation. 
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3. Inhibition of β-haematin formation and Parasite growth 
 
3.1 Introduction 
 The emergence of parasite resistance to quinoline-based antimalarial drugs such as 
chloroquine has led to a need for new and effective drugs.  For identification and 
development of these new scaffolds, the structure-activity model for chloroquine is a useful 
exemplar used for selection and synthesis of various analogues of other templates in order 
to explore structure activity relationships and to further develop them into potential 
haemozoin/β-haematin inhibitors.  
 
Structure-activity relationships (SARs) attempt to find the structural features responsible for  
physico-chemical factors that contribute to the activity of a compound, for example, 
biological activity of a drug. A good SAR model helps in narrowing down the route leading to 
the most active analogue specific to a certain target. SAR can be qualitative as well as 
quantitative (QSAR). For the latter, certain free energy molecular descriptors such as 
Hammett constants, quantum mechanical and structural descriptors (for example 
polarizability of a compound, molar refractivity, Van der Waals volume, HOMO/LUMO 
energy) as well as other 2D descriptors such as molecular weight and logP are used to look 
for correlations  with the IC50 values of a series of compounds.
86, 116 Thus analysis of such 
correlations yields a model which gives insight to the influences these factors have on 
activity. Correlation analyses between the IC50 values of the analogues synthesised in this 
work and molecular descriptors (calculated using MarvinSketch ChemAxon version 6.3.1)117 
described below were found to be significant: 
i) Fraction of saturated (sp3 hybridised) carbon atoms (Fsp3):this describes the 
degree of saturation of the molecule by calculating the ratio of number of 
saturated carbon atoms in the molecule over the total number of carbon atoms. 
This is closely associated with solubility of the molecule.118, 119  
ii) Molecular polarizability: this is a measure of the ability of a non-polar neutral 
molecule to be distorted after induction by a charged particle. It provides 
information about the drug-receptor interactions such as dispersion forces.120, 121 
iii) Molecular refractivity: this describes the size and volume of the molecule.121 
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iv) Van der Waals volume: the actual volume of a molecule. It is important for 
understanding the biological compatibility of the compound which includes its 
ability to be absorbed and penetrate through membrane barriers and is closely 
associated with molecular refractivity.122 
v) Molecular weight: the mass of the molecule. Likewise this is related to the ability 
of a molecule to diffuse through membranes to its target (or receptor) site.  
vi) Logarithm of the partition coefficient (logP): a measure of lipophilicity of a 
molecule. This indicates the relative solubility of a drug in a lipid membrane. 
Positive values of this constant indicate that the substance is hydrophobic while 
negative values indicate hydrophilicity of the molecule.  
 
3.2 Measurement of β-haematin formation 
The in vitro β-haematin inhibition assay was performed in 96-well plates using the method 
described by Carter et al.99 The method makes use of a non-ionic lipophilic detergent known 
as Nonidet P-40 (NP-40) to mimick the role of neutral lipid bodies inside the parasite 
digestive food vacoule associated with promoting haemozoin formation. The use of neutral 
lipid droplets in high-throughput screening is time consuming and requires expensive 
materials hence their use is unfeasible. The detergent is believed to have the ability of 
aligning free haem at the micelle-water interface. Its hydrophobic side chain facilitates an 
ordered packing, assisting in π-stacking of haem porphryin groups, hence promoting β-
haematin formation. The detergent assay significantly reduces the analysis time to about 5 
hours, whilst also being user-friendly and requiring less expensive materials. The structure 
of NP-40 is shown in Figure 38 below. Modifications and validation of the method previously 
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Figure 38: The structure of the NP-40 detergent showing the hydrophobic tail that is believed to 
assist in π-stacking with haem vinyl groups therefore promoting crystallisation to β-haematin. 91  
 
Addition of acetate buffer (pH 4.8 ± 0.1) initiates the β-haematin crystallisation process. 
Assay analysis was achieved using the colourimetric pyridine-ferrichrome method 
developed by Ncokazi and Egan.123 The method determines the IC50 value of the inhibitor by 
measuring the percentage of free haematin in the haematin/ β-haematin mixture. It 
involves detecting non-crystallised haematin by selectively coordinating it with pyridine 
present in a 5% (v/v) pyridine solution (pH 7.4).  The strong field pyridine ligand displaces 
the axial water ligands coordinated to the iron (Fe(III)) centre of free haematin, forming a 
monomeric low-spin, bis-pyridine complex  (pyridine2-Fe(III)PPIX) with haematin without 
affecting β-haematin, Figure 39. The complex has an intense orange colour. 
 
Figure 39:  The low-spin pyridine2-Fe(III)PPIX complex.
91 Reprinted from International Journal for 
Parasitology-Drugs and Drug Resistance, Vol 4, Sandlin, Rebecca D. Fong, Kim Y. Wicht, Kathryn J. 
Carrell, Holly M. Egan, Timothy J. Wright, David W., The role of antimalarial treatment in the 
elimination of malaria, 316-325., Copyright (2014), with permission from Elsevier 
The intense absorption peak at 405 nm is used to produce a concentration dependent 
inhibition curve which is then fitted to a sigmoidal dose response equation using non-linear 
least squares fitting in Graph Prism v3.02.124 This is in the form of a plot of absorbance at 
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405 nm against the log of the inhibitor concentration. The IC50 value for the analogue is then 
found. Figure 40 shows a dose-response curve of analogue 23 as a typical example.  
 
Figure 40: The sigmoidal dose response curve for analogue 23 
 
The β-haematin formation inhibitor amodiaquine, was used as a positive control to validate 
the use of the NP-40 detergent assay for screening of compounds. The IC50 for the drug was 
found to be 18 µM in good agreement with the IC50 of 21.0 µM obtained using the same 
positive control in a 384-well plate reported by Sandlin et.al.90 Following validation, serial 
dilutions of different analogues in 96-well plates were then performed in order to 
determine their IC50s. These data were then used in structure activity relationship studies. 
 
3.3 Structure activity relationships for β-haematin inhibition 
3.3.1 Series 1: Variation of the ester component (R and R’). 
Series 1 consisted of twenty-one compounds in which the side chains of the ester (or in one 
case a ketone) groups were varied, Figure 41. 
  
Figure 41: 1,4-dihydropyridine ester (or ketone) compounds tested. 
Log[23] 
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a) Compound 21  and the alkyl and benzyl substituents 
The IC50 values for the β-haematin inhibition assay for 21  and the alkyl analogues are shown 
in Table 7 below. 
 
Table 7:  The β-haematin inhibition IC50 values for the alkyl derivatives 
 
The derivatives showed no direct correlation between the logIC50 for inhibition of β-
haematin formation (LogβIC50) and any of the free energy parameters. However it was 
observed that a shift to larger alkyl groups increased the activity of the compound probably 
indicating the influence of hydrophobicity (log P) on activity. The isopropyl analogue 




Analogue R=R' IC₅₀ (µM) logIC₅₀ (µM)
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Table 8:  The β-haematin inhibition activity of alkyl analogues in an ascending order.  
 
 
For the benzyl series multiple correlation analysis revealed a statistically significant 
correlation at the 95% confidence level between LogβIC50 and Log P together with one of 
several constants (Table 10). In all cases it was observed that increasing the hydrophobicity 
of the compound resulted in a decrease in IC50 thus leading to a more active analogue. The 
presence of groups that have more saturated (sp3) carbon atoms and lower molecular 
weight also contributed positively to the activity against β-haematin formation of the 1,4-
dihydropyridine benzyl esters. Table 9 shows the IC50 values for this series. 
 






Analogue 22 23 26 25
IC₅₀ (µM) 350±14 115±3.9 59±5 38±2
LogP 3.08 3.8 5.19 4.63
Analogue R=R' IC₅₀ (µM) logIC₅₀ (µM) Analogue R=R' IC₅₀ (µM) logIC₅₀ (µM)
29 80954 4.91 34 54±4.6 1.73±0.04
30 76±5.3 1.88±0.03 35 25±2 1.40±0.04
31 57±2.7 1.76±0.02 36 51±4.5 1.71±0.04
32 30±2.8 1.48±0.04 37 62±3.9 1.79±0.03
33 57±3.1 1.76±0.02 38 58±3.0 1.76±0.02
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Table 10: Summary of multiple correlation results for the benzyl derivatives 
 
 
In spite of the statistical significance on these correlations (Table 10), a two-tailed t-test on 
each individual parameter revealed that only Log P correlated with the IC50 at the 90 % 
confidence level. The other parameters correlated only at the 80 and 75 % levels (Table 11). 
Other parameters such as the Fsp3, molecular weight and van der Waals volume, might also 
contribute to the activity although this is even less certain based on statistical confidence 
levels. Table 11 shows a summary for the t-test results. 
 
Table 11: Summary of t-test results. 
 
An attempt to combine the two ester groups for QSAR analysis was unsuccessful, since no 
correlations could be found. 
 
b) Analogues containing an N-heterocycle in the ester side chain 
Table 12 shows the β-haematin inhibition results for analogues 43  and 44 selected to study 
the possible effect of pH trapping. Unfortunately attachment of a N-heterocyclic group on 







Parameter Coefficient Log P coefficient R-squared F-value
F-critical at 
95% interval
1 Fsp³ -5.39 -1.12 0.64 6.13 4.74
2 Mr 0.00674 -1.53 0.64 6.31 4.74
3
Van der vaals volume 
(Å³)
0.00355 -1.22 0.6 5.2 4.74
QSAR 
model







1 Fsp³ 0.85 3.36 0.711 (75%) 3.00 (99%)
2 Mr 0.933 2.81 0.896 (80%) 2.37 (98%)
3
Van der vaals volume 
(Å³)
0.127 1.57 insignificant 1.45  (90%)
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Table 12: β-haematin inhibition IC50 values for N-heterocycle analogues. 
 
 
c) Effect of removing symmetry 
In order to test the effect if any of changing from achiral to chiral analogues on β-haematin 
formation, the asymmetrical analogue 41 was compared to the two symmetrical 
compounds (23 and 26) possessing the two esters found in 41. The results are in the table 
13 below 
 
Table 13:  Results for analogue 41 
 
 
The results showed some improvement in activity for 41 compared to 23 and reduction with 
respect to 26 indicating little or no obvious influence of chirality on inhibition of β-haematin 
formation. 
 
3.3.2 Series 2: Variations on the R’’ group 
The results for the four analogues selected to study functional group influences at the 2 and 
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The presence of the ethyl group at R’’ position decreases the IC50 value in analogues 39 and 
40 improving activity of these analogues relative to their methyl analogues 22 and 23. This 
also fits with the idea that increasing logP improves activity. 
 
3.3.3 Series 3: The importance of the NH group on the dihydropyridine ring 
In contrast to 23, 42 was found to be inactive (Table 15) indicating that hydrogen bond 
donor ability of the nitrogen atom is probably crucial to β-haematin inhibition activity. Loss 
of this interaction by attachment of the methyl group is most likely the cause of loss of β-
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3.3.4 Series 4: Effect of oxidation to a pyridine 
It was hypothesised that moving from a dihydropyrdine to the aromatic pyridine ring will 
increase π-π stacking interactions and thus improve activity. However, the β-haematin 
inhibition results rather displayed the opposite trend. All five oxidised analogues (Figure 42) 
exhibited >800 µM IC50 values thus indicating no potency against β-haematin formation. 
These results support the hypothesis that hydrogen bonding of the NH group is crucial for 
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Figure 42:  The 1,4-pyridine compounds tested against β-haematin formation. All were inactive. 
 
3.4 Measurement of parasite growth inhibition 
The in vitro antiplasmodial activity testing for the 1,4-DHP series was performed by the 
University of Cape Town Health Sciences Faculty, Division of Pharmacology, using a method 
previously reported by Zishiri et al.125 The method used to test the compounds against the 
asexual RBC stages of a P. falciparum chloroquine sensitive strain (NF54).126 The lactate 
dehydrogenase assay of Makler et al. was used for quantitative assessment of the 
antiplasmodial activity of each inhibitor.127 The antimalarial drugs chloroquine and 
artesunate were used as controls for the experiments. 
 
3.5 Structure activity relationships for in vitro antimalarial activity 
3.5.1 Series 1: Variation in the ester group. 
a) Compound 21  and the alkyl and benzyl series 
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Table 16:  The results of the in vitro antimalarial assay for 21 and the 1,4-DHP alkyl esters. 
 
*Denotes single determination 
 
It was hypothesised that activity might correlate with logP, but the correlation was poor 
(Figure 43a). However, 21, 25  and 27 looked like they may represent outliers and when 
omitted a good correlation was obtained (Figure 43b) and conformed to equation 3.4.1. 
  
Using single linear correlation analysis, logIC50 was found to correlate with logP (r
2 = 0.94). 
The correlation yielded an empirical equation 3.4.1 
LogIC50= -7.91logP + 7.11……. eq(3.4.1) 
The analysis revealed that parasite growth inhibition activity increases with an increase in 
hydrophobicity of the compound. Hydrophobicity allows for membrane solubility and also 
promotes interaction with haem, which is also hydrophobic.101, 128-130  
Analogue R=R' IC₅₀ (µM) logIC₅₀ (µM)
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Figure 43a:  The linear regression plot of logIC50 vs logP for 1,4-DHP alkyl esters (including 21, 25 and 
27). Empirical equation: LogIC50= -0.110logP + 0.828 ( r
2 = 0.24)  
 
 
Figure 43b: The linear regression plot of logIC50 vs logP for 1,4-DHP alkyl esters (excluding 21, 25 and 
27). LogP is inversely proportional to antiplasmodium activity. 
 
At the 95% confidence level, multiple linear regression analysis for the benzyl substituents 
(see Table 17 for the IC50 values) revealed a correlation between the logIC50 value of the 
compound with Fsp3 and molecular weight of the analogues (r2= 0.64) 
Empirical equation: Log IC50 = 0.0065Mr + 8.07Fsp
3- 4.78 …..eq (3.4.2) 
The observations suggested that analogues with high molecular weight and possessing more 
saturated carbon atoms possess increased IC50 values leading to a decrease in activity of the 
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small surface areas required for diffusion through membranes to access their specific target 
sites. This has been seen for many haemozoin formation inhibiting antimalarial drugs.128, 130-
132 The empirical equation (3.5.2) which was determined using the overall F2,7 distribution 
with the critical F-value of 4.74 (F= 6.38 > F2,7 = 4.74), is statistically significant at the 95% 
confidence level. Looking at the coefficient values in the equation, it is observed that degree 
of saturation of analogues has more influence on activity than molecular weight, signifying 
that π-stacking interactions may be of greater importance. Molecules that are unsaturated 
have a greater number of conjugated electrons (π-electrons) therefore increasing strength 
of association between the inhibitor and the haem porphyrin ring which promotes inhibition 
of haemozoin formation. 101 A two-tailed t-test done on individual parameters (t = 3.22 (Mr), 
2.78 (Fsp3) > tcrit = 2.45) showed that both Mr and Fsp
3 correlated significantly with logIC50 at 
the 98% confidence level. Figure 44 is a multiple linear regression plot of predicted against 
observed IC50 of the 1,4-dihydropyridine benzyl ester analogues.  
 
 
Figure 44: The linear regression plot of observed vs predicted logIC50 for antiplasmodium activity of 
1,4-DHP benzyl ester compounds. The plot displays a positive linear correlation of parasite growth 
inhibition (logIC50) with Mr and Fsp
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Table 17: The results of the in vitro antimalarial assay for the 1,4-DHP benzyl esters. 
 
 
The antiplasmodium activity of a compound appears to be greatly reduced when it is a 
disubstituted benzyl analogue. For mono substituted analogues, a greater reduction of 
activity occurs for para substituents than the ortho and meta cases. Except for 37 electron-
withdrawing substituents led to greater activity. This is in agreement with the hypothesis 
that electron-releasing substituents increase electron density in the aromatic ring 
weakening the π-π stacking interactions of the compound with the haem macrocycle. 
 
b)  Analogues containing an N-heterocycle in the ester side chain 
It was hypothesised that introducing a second amine group on the 1,4-DHP molecule would 
increase basicity of the molecule therefore resulting in pH trapping inside the parasite 
digestive vacuole. The presence of a tertiary amine in the molecule can permit penetration 
across the cell membrane into the acidic food vacuole where it is protonated resulting in 
accumulation of charged species and consequent inhibition of the haem detoxifiction 
pathway. The results for the two analogues selected for studying this phenomenon are 




Analogue R=R' IC₅₀ (µM) logIC₅₀ (µM) Analogue R=R' IC₅₀ (µM) logIC₅₀ (µM)
29 1.1±0.1 0.05±0.04 34 2.3±0.3 0.36±0.06
30 7.5±2.6 0.88±0.2 35 0.8±0.2 (-0.1)±0.1
31 4.5±0.5 0.65±0.05 36 8.3±0.8 0.92±0.04
32 11±0.7 1.04±0.03 37 18±4.9 1.3±0.1
33 5.2±0.9 0.72±0.08 38 6.8±0.6 0.83±0.04
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Table 18: Parasite growth inhibition results for compounds 43 and 44. 
 
 
Compound 43 showed fairly strong activity while 44 showed only very weak activity. The 
weak antiplasmodium activity of compound 44 may be primary because of the lack of β-
haematin inhibiting activity. It may also be caused by the absence of the second nitrogen 
atom of the piperazine ring which increases its lipophilicity. This also increases its solubilty 
in membranes more than in aqueous solution leading to poor accumulation in the digestive 
vacuole as seen by the vacuolar accumulation ratio (VAR). The ratio is predicted using the 
Henderson-Hasselbalch equation which uses the distribution coefficient (logD) to calculate 
the lipophilicity of an ionised compound at various pH values assuming that drug diffuses 
across membranes without assistance of transporters (see experimental section for the 
equation of both VAR and lipid accumulation ratio (LAR)).131, 133-135 Calculations predicted 
that 43 would accumulate in the food vacuole 125 times more than 44. Although this 
compound exhibited very poor β-haematin inhibition activity, its activity could possibly still 
be attributed to weak β-haematin inhibition combined with the great digestive vacuole 
accumulation resulting in inhibition of haemozoin at higher concentrations compared to 44. 
However, since both analogues exhibited no β-haematin inhibition at the highest 
concentration that could be tested, this could not be confirmed and their activity may also 
be ascribed to a different mechanism of action (which nonetheless involves pH trapping), or 
alternatively the NP-40 assay does not adequately mimic the effect of lipids in the case of 
these specific derivatives.  
 
c) Effects of removal of symmetry 
Stereoisomerism plays an important role in biological molecular recognition of drugs by 
their receptors. A chiral molecule has greater three dimensional spatial complexities which 
increases its receptor affinity and recognition of functional groups by its potential target 
Compound IC₅₀ (µM) VAR LAR Log P
43 0.680±0.01 17783 2.43 4.62
44 3.9±0.6 2.83 4.58 4.82
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molecule.136, 137 It is clear from Table 19 that the chirality possessed by 41 has a significant 
effect on the biological activity. Since this has no effect on β-haematin inhibition, it either 
also points to another mechanism of action or a role for transporters in uptake of these 
compounds which discriminates between them. 
 
Table 19: The SAR results for the effect of symmetry study. 
 
 * single determination 
3.5.2 Series 2: Variations on the R’’ group 
Lengthening the alkyl group at positions 2 and 6 on the dihydropyridine ring appears to be 
well tolerated and influences activity to some extent as seen in Table 20 below. The effect 
seems to parallel β-haematin inhibition. 
 
Table 20:  IC50 values for R’’ position analogues 
 
* single determination 
 
3.5.3 Series 3: The role of the NH group in the dihydropyridine ring 
The results of the in vitro antimalarial assay for the alkylated derivative at the NH group 
were similar to those found for β-haematin inhibition with the alkylated derivative showing 
reduced activity. However, the reduction in activity was less marked.  Table 21 shows the 
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Table 21:  Parasite growth inhibition IC50 results for evaluating H-bond donor influences on activity. 
 
* single determination 
 
3.5.4 Series 4: Oxidation to pyridines 
Although the pyridine molecule provides the electron cloud system with more π-electrons 
which can π-stack with the hydrophobic haem macrocycle whilst having an electron 
deficient nitrogen atom, the lack of β-haematin inhibition described previously seems to 
result in poor parasite growth inhibition activity. This outweighs any advantages conferred 
by the rigidity of the molecule (sp2 hybridised carbons). Oxidation to the pyridine of the 1,4-
dihydropyridine nucleus resulted in weak or no antiplasmodium activity, table 22. 
 
Table 22: The IC50’s for the oxidised derivatives. 
 
 
3.6 Relationship between activity against parasite growth and β-haematin formation  
Although a direct correlation between the logIC50  for parasite inhibition with that for β-
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revealed that the two inhibition activities did generally parallel each other with the 
exception of analogue 43  which showed no or very weak activity against β-haematin 
formation with good biological activity. Possible reasons for the lack of a direct correlation 
may be that the detergent assay did not adequately mimic the role of lipids for these 
compounds or that their access across the digestive vacuole membrane is limited.  
The expected 1000 fold parasite digestive vacuole accumulation of 43 suggests two possible 
reasons for its activity: 
i) Compound accumulation to levels where it can inhibit haemozoin at high 
concentrations 
ii) It may exert its antimalarial potency via a different mechanism of action 
(example inhibition of a digestive vacuole channel or transporter or protease 
inhibition within the digestive vacuole) to inhibit parasite growth. 
 
 In case of 1,4-DHP esters, the activity against parasite growth and β-haematin formation 
increased with increasing hydrophobicity of the analogue. A statistically significant trend 
was found for parasite activity when analogues 27, 25 and 21 were omitted from the data. 
This indicated that other factors also played a role in activity of compounds. The inactivity of 
21 against both β-haematin formation and parasite growth can most likely be attributed to 
the absence of an ester group in this ketone derivative which may be essential for activity. 
 
The β-haematin inhibition activity for benzyl derivatives showed a more complex 
dependency on several factors such as log P, size and saturation of molecules. However for 
inhibition of parasite growth a quantitative correlation revealed that increasing molecular 
weight and number of saturated carbon atoms in the molecule decrease the activity of a 
compound. Apart from 29 which exhibited a non-existent activity against β-haematin 
formation, the activity of the benzyl series showed parallel behaviour between parasite and 
β-haematin inhibition. 
 
Alkylation on the nitrogen abolishes or weakens activity of the molecule suggesting 
importance of hydrogen-bonding. For compounds 39 and 40, activity slightly increased 
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suggesting limited influence of substituents at 2 and 6 positions on both antiplasmodium 
and β-haematin activities.  
3.7 Conclusions 
Based on the results found in the present study, a structure-activity relationship model 
using molecular descriptors for antimalarial activity of a 1,4-DHP molecule was deduced. 
These structural factors are as follows: 
i) Introduction of chirality appears to have an influence on antiplasmodial activity 
with little or no effect on β-haematin formation. 
ii) Loss of hydrogen bond donor attributes of the nitrogen atom in the 
dihydropyridine ring results in elimination of activity. 
iii) The 1,4-DHP nucleus is essential for maintaining activity. Upon oxidation of the 
ring  to a pyridine group, activity is either obliterated or substantially decreased. 
iv) Changes to a larger alkyl group at the 2 and 6 (R’’) position are well tolerated, 
slightly increasing activity. 
v) Vacuolar accumulation is probably enhanced by presence of a lipophilic N-
heterocycle, but to the detriment of haemozoin inhibition.  
vi) For the alkyl esters, larger hydrophobic groups greatly increase activity of the 
compound. 
vii) Saturation and increased molecular weight of the molecule has a negative effect 
on parasite activity for 1,4-DHP benzyl esters.  
 
Overall, the shape of a 1,4-DHP molecule is of importance for specific recognition and 
interaction with haem (haemozoin) influencing its activity. Figure 45 shows the SAR model 
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Figure 45: The proposed SAR model in the 1,4-DHP template for antimalarial activity for the current 
project based on 40 1,4-DHP compounds (inclusive of the 12 analogues from a previous study 
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4. Conclusions and Future-Work 
 
4.1 General Conclusions 
The key objective of the project was to synthesise analogues of the 1,4-DHP molecule by 
performing various positional structural alterations and thereafter explore structure activity 
relationships  and using statistical correlation analysis to also investigate quantitative 
structure activity relationships influencing both inhibition of β-haematin formation and 
parasite growth. The one pot experimentally convenient Hantzsch pyridine reaction was 
successfully used for the synthesis and testing of forty 1,4-DHP compounds (including 12 
compounds from previous work) selected to cover a range of activity space guided by the 
Topliss scheme. In agreement with literature, microwave irradiation was used to accelerate 
the reaction whilst obtaining high product yields. A transesterification process for the 
synthesis of a range of acetoacetate substrates required for Hantzsch reaction was carried 
out using a Dean stark apparatus to drive formation of products. This proved efficient for 
the synthesis of many derivatives with varied groups. 
 
Studies revealed three analogues (Figure 46) that showed promising antimalarial potency. 
These were: the chiral analogue 41 (βIC50 = 74±4 and parasite IC50 = 0.600±0.007 µM); the 
symmetrical benzyl ester 35 (βIC50 = 25±2 and parasite IC50 = 0.8±0.2 µM); and the 
symmetrical alkyl ester 25 (βIC50 = 38±2 and parasite IC50 = 0.5±0.1 µM. 
 
Figure 46:  The structures of 1,4-DHP analogues showing promising antimalarial activity. 
 
The parasite activity of 41 may reflect the complexity of biological targets or transporters 
which frequently display preferences for a stereospecific molecule.  Although this may be 
Chapter 4: Conclusions and Future-Work 
83 | P a g e  
 
true, the remarkable activity of 25 suggests that antimalarial activity of the 1,4-DHP scaffold 
may be more complicated than speculated, hence a more in depth analysis is required. 
Correlation studies for 1,4-DHP benzyl esters revealed that low molecular weight and low 
degree of saturation correlated well with activity of the compound. Since only a relatively 
small number of derivatives were synthesised for physico-chemical studies, correlation of 
more than two parameters with log IC50 at once is not statistically valid owing to over 
determination. This may have hindered discovery of more complex underlying SARs. 
 
With respect to the various analogues modified at the ester groups, quantitative correlation 
results provided a useful structure-activity model which may be a powerful tool for 




The structure-activity relationship model presented in this project mainly focused on 
structural influences possessed by the ester component of the 1,4-DHP molecule. As a 
result, only a few analogues with modifications on the R’’ and R’’’ positions were 
synthesised. Hence for validation purposes, a quantitative study involving more extensive 
exploration at these positions would be worthwhile. Similarly, introduction of further 
modifications on the 4-phenyl ring may prove a fruitful avenue of investigation.  
Conformational analysis using molecular mechanics modelling could be of interest for 
insight into intermolecular forces and structural differences between the inactive pyridine 
analogues and the active 1,4-dihydropyidines. 
 
The ability of the compounds to inhibit haemozoin in the parasite has not yet been 
investigated. This will be required. Indeed, the good activity of 43 against the parasite 
despite poor activity against β-haematin formation indicates that at least some of these 
analogues may have other mechanisms of action which need to be explored. 
 
Finally, investigation of the absorption, distribution, metabolism, excretion and toxicity 
properties of the compounds would need to be investigated to establish their potential for 
further drug development. 
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Chapter 5: Experimental Section 
 
5.1 Organic Synthesis 
Materials and techniques: 
Reagents were purchased from Sigma Aldrich and were used without further purification. 
Thin layer Chromatography (TLC) was used to monitor reaction progression and was done 
on precoated silica gel 60 F254 plates purchased from Merck. Microwave reactions were 
done on a CEM Discover microwave machine using 0.0 bar of pressure and 250 W of power. 
Reaction progression on TLC plates were visualised by staining (anisaldehyde:sulphuric acid 
(50:50))and by ultraviolet light. 
Melting points are uncorrected and were measured on a Riechert-Jung Thermovar hot-stage 
microscope. 1H NMR and 13C NMR spectra were obtained on either 400 MHz or 300 MHz 
Bruker spectrometers or on a 300 MHz Varian Mercury Unity spectrometer. Chemical shifts 
(δ) are presented in parts per million (ppm) and coupling constants (J) in Hertz (Hz). Signal 
multiplicity are represented by: s for singlet, bs for broad singlet, d for doublet, dd for 
doublet of doublet, ddd for doublet of doublet of doublet, ddt for doublet of doublet of 
triplet, t for triplet and m for a multiplet. The reference chemical shifts for CDCl3 are 7.26 
ppm in the 1H NMR and 77.16 ppm in the 13C NMR spectra. 
Infrared spectra were recorded using A225/Q platinum ATR diamond infrared spectrum 
machine. The high resolution mass spectrometry was recorded on a Waters Synapt G2 
HRMS instrument at the Central Analytical Facilities, University of Stellenbosch. High 
Pressure liquid chromatography was recorded on an Agilent technologies 1220 Infinity LC 
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General Procedure for  synthesis of the benzyl alcohols.138 
The relevant aldehyde (17.0 mmol) was dissolved in ethanol (10.0 ml) at 0°C followed by 
portion-wise addition of sodium borohydride (25.0 mmol, 1.50 eq). The reaction was then 
stirred at room temperature under N2 for five minutes before being quenched with aqueous 
ammonium chloride. Thin layer chromatography (TLC) revealed a spot-to-spot conversion. 
Ethanol was removed under reduced pressure and cold water (15.0 mL) was added and the 
solution extracted using ethyl acetate (3 x 30.0 mL). The ethyl acetate extracts were dried 
over magnesium sulfate (MgSO4), the solvent removed under reduced pressure and the 
product dried under vacuum. The product was used in the subsequent step without further 
purification. 
 
4-Methylbenzyl alcohol (1)139 
                                                                
Compound 1 (1.90 g, 94%) was obtained as colourless solid; 1H NMR (400 MHz, CDCl3) δ 7.27 
(2H, d, J = 8.1 Hz, H-3), 7.17 (2H, d, J = 8.1 Hz, H-2), 4.92 (1H, bs, OH) 4.65 (2H, s, ArCH2), 
2.35 (3H, s, ArMe); 
13C NMR (100 MHz, CDCl3) δ 137.9 (C-1), 137.5 (C-4), 129.4 (C-3), 127.2 (C-
2), 65.3 (ArCH2), 21.2 (ArMe). 
 
3-Methylbenzyl alcohol (2)140 
 
Compound 2 (1.88 g, 91%) was obtained as a yellow liquid. 1H NMR (400 MHz, CDCl3) δ 7.28 
(1H, d, J = 7.2 Hz, H-6), 7.24 (1H, d, J = 8.1 Hz, H-4), 7.16 (1H, m, H-5), 7.12 (1H, d, J = 2.6 Hz, 
H-2), 4.98 (1H, bs, OH), 4.65 (2H, s, ArCH2), 2.37 (3H, s, ArMe); 
13C NMR (100 MHz, CDCl3) δ 
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3,4-Dichlorobenzyl alcohol (3) 
                                                                            
Compound 3 (2.86, 95%) was obtained as a colourless solid; 1H NMR (400 MHz, CDCl3) δ  
7.47 (1H, d, J = 2.1 Hz, H-2), 7.43 (1H, d, J = 8.1 Hz, H-5), 7.19 (1H, dd, J = 8.1, 2.1 Hz, H-6), 
4.88 (1H, bs, OH), 4.67 (2H, s, ArCH2); 
13C NMR (100 MHz, CDCl3) δ  143.2 (C-1), 134.9 (C-4), 
133.7 (C-3), 132.8 (C-5), 131.0 (C-2), 128.0 (C-6), 66.2 (ArCH2) 
 
2,4-Dichlorobenzyl alcohol (4)141 
                                                               
 
Compound 4 (2.88 g, 95%) was obtained as a colourless solid; 1H NMR (400 MHz, CDCl3) δ 
7.43 (1H, d, J = 8.2 Hz, H-6), 7.38 (1H, d, J = 2.1  Hz, H-3), 7.26 (1H, dd, J = 8.2,  2.0 Hz, H-5), 
4.75 (2H, s, ArCH2), 2.00 (1H,s, OH). 
13C NMR (100 MHz, CDCl3) δ 136.7 (C-1), 133.9 (C-4), 
133.2 (C-2), 129.4 (C-6), 129.2 (C-3), 127.3 (C-5), 62.2 (ArCH2). 
 
General Procedure for synthesis of acetoacetate ester analogues: 111 
Zinc (1.31 g, 20.0 mmol) was dissolved in anhydrous toluene (20.0 mL) at 110 °C, methyl 
acetoacetate (1.13 ml, 10.0 mmol) was then added. Addition of the alcohol (12.0 mmol) and 
a catalytic amount of iodine (254 mg, 1.00 mmol) respectively was then performed. The 
mixture was subsequently refluxed under N2 and methanol removed by distillation. TLC 
using a solvent system of hexane/ ethyl acetate (3:1) was used to monitor the reaction 
progress, but generally reaction times were in the order of 3 hours to overnight. De-ionised 
water was used to quench the reaction, and the mixture filtered through Celite and washed 
with cold toluene (3 x 15.0 ml). Removal of the toluene was done under vacuum. Ice-cold 
water (10.0 ml) followed by brine (25.0 mL) were added to the residue and extraction 
performed using DCM (3 x 20.0 mL). The organic extracts were dried with MgSO4 and the 
solvent evaporated under reduced pressure. Column chromatography was performed using 
hexane/ ethyl acetate (3:1) as eluent.  
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Isopropyl acetoacetate (5)142 
 
The reaction yielded compound 5 (696 mg, 48%) as a colourless liquid. 1H NMR (400 MHz, 
CDCl3) δ  5.06 (1H, sep, OCH), 3.40 (2H, s, H-3), 2.25 (3H, s, H-1),  1.25 (6H, d, J = 6.3 Hz, 
Meisopropyl); 
13C NMR (100 MHz, CDCl3) δ 200.6 (C-2), 166.6 (C-4), 69.0 (OCH), 50.5 (C-3), 30.0 
(C-1), 21.7 (Meisopropyl). 
 
Cyclohexyl acetoacetate (6)142                                                    
 
The reaction yielded compound 6 (1.57 g, 85%) as a colourless liquid.  1H NMR (400 MHz, 
CDCl3) δ 4.84-4.80 (1H, m, OCH (1’)), 3.41 (2H, s, H-3), 2.26 (3H, s, H-1), 1.85, 1.73 (4H, m, H-
2’), 1.53 (2H, m, H-4’), 1.35 (4H, m, H-3’); 13C NMR (100 MHz, CDCl3) δ 200.6 (C-2), 166.6 (C-
4), 73.8 (OCH), 50.5 (C-3), 31.4 (C-2’), 29.9 (C-1), 25.2 (C-4’), 23.6 (C-3’). 
 
Cyclopentyl acetoacetate (7) 142                                                 
 
 The reaction yielded compound 7 (494 mg, 29%) as a colourless liquid.  1H NMR (400 MHz, 
CDCl3) δ 5.20-5.12 (1H, m, OCH (1’)), 3.20 (2H, s, H-3), 2.17 (3H, s, H-1), 1.80-1.65 (4H, m, H-
2’), 1.63, 1.52 (4H, m, H-3’); 13C NMR (100 MHz, CDCl3) δ  200.6 (C-2), 166.9 (C-4), 78.3 
(OCH), 50.4 (C-3), 32.6 (C-2’), 30.0 (C-1), 23.7 (C-3’). 
 
Benzyl acetoacetate (8) 142 
 
The reaction yielded compound 8 (1.54 g, 80%) as a colourless liquid. 1H NMR (400 MHz, 
CDCl3) δ 7.30-7.20 (5H, m, Ar-H), 5.10 (2H, s, OCH2), 3.42 (2H, s, H-3), 2.17 (3H, s, H-1). 
13C 
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NMR (100 MHz, CDCl3) δ 200.2 (C-2), 166.9 (C-4), 135.3 (C-1’), 128.6 (C-3’), 128.4 (C-4’), 
128.3 (C-2’), 67.1 (OCH2), 50.0 (C-3), 30.1 (C-1). 
 
2-Chlorobenzyl acetoacetate (9)143 
 
The reaction mixture was refluxed overnight yielding compound 9 (1.92 g, 85%) as 
colourless crystals.  1H NMR (400 MHz, CDCl3) δ 7.42-7.12 (4H, m, Ar-H), 5.30 (2H, s, OCH2), 
3.56 (2H,s, H-3), 2.30 (3H, s, H-1); 13C NMR (100 MHz, CDCl3) δ 200.5 (C-2), 166.8 (C-4), 138.2 
(C-1’), 130.2 (C-2’), 129.4 (C-6’), 128.9 (C-3’), 128.8 (C-4’), 127.0 (C-5’), 62.9 (OCH2), 50.0 (C-
3), 30.2 (C-1). 
 
4-Chlorobenzyl acetoacetate (10)144 
 
The reaction yielded compound 10 (1.87 g, 83%) as a pale-yellow liquid.  1H NMR (400 MHz, 
CDCl3) δ 7.26 (2H, d, J = 8.8 Hz, H-3’), 7.22 (2H, d, J = 8.8 Hz, H-2’) 5.06 (2H, s, OCH2), 3.42 
(2H, s, H-3), 2.17 (3H, s, H-1); 13C NMR (100 MHz, CDCl3) δ 200.0 (C-2), 166.8 (C-4), 134.5 (C-
1’), 133.9 (C-4’), 129.8 (C-3’), 128.8 (C-2’), 66.3 (OCH2), 50.0 (C-3), 30.2 (C-1). 
 
3-Chlorobenzyl acetoacetate (11)145 
 
The reaction yielded compound 11 (1.80 g, 79%) as a colourless liquid.  1H NMR (400 MHz, 
CDCl3) δ 7.40-7.35 (1H, m, H-5’), 7.33-7.30 (3H, m, H-2’, H-4’ and H-6’), 5.17 (2H, s, OCH2), 
3.54 (2H, s, H-3), 2.29 (3H, s, H-1); 13C NMR (100 MHz, CDCl3) δ 200.2 (C-2), 166.8 (C-4), 
137.3 (C-1’), 134.5 (C-3’), 130.0 (C-5’), 128.6 (C-4’), 128.3 (C-6’), 126.3 (C-2’), 66.2 (OCH2), 
49.9 (C-3), 30.2 (C-1). 
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4-Bromobenzyl acetoacetate (12)143 
 
 The reaction yielded compound 12 (1.78 g, 66%) as a colourless solid. 1H NMR (400 MHz, 
CDCl3) δ 7.50 (2H, d, J = 6.8 Hz, H-3’), 7.24 (2H, d, J = 6.8  Hz, H-2’), 5.11 (2H, s, OCH2), 3.49 
(2H, s, H-3), 2.24 (3H, s, H-1); 13C NMR (100 MHz, CDCl3) δ 200.2 (C-2), 166.8 (C-4), 134.3 (C-
1’), 131.8 (C-3’), 130.0 (C-2’), 122.5 (C-4’), 66.3 (OCH2), 49.9 (C-3), 30.2 (C-1). 
 
4-Methylbenzyl acetoacetate (13)144 
                                                                    
 
The reaction yielded compound 13 (1.56 g, 76%) as a colourless liquid.  1H NMR (400 MHz, 
CDCl3) δ 7.26 (2H, d, J = 8.0 Hz, H-2’), 7.18 (2H, d, J = 8.0 Hz, H-3’), 5.14 (2H, s, OCH2), 3.48 
(2H, s, H-3), 2.36 (3H, s, ArMe), 2.24 (3H, s, H-1); 
13C NMR (100 MHz, CDCl3) δ 200.5 (C-2), 
167.0 (C-4), 138.5 (C-1’), 132.3 (C-4’), 129.3 (C-2’), 128.6 (C-3’), 67.2 (OCH2), 50.1 (C-3), 30.2 
(C-1), 21.2 (ArMe). 
 
3-Methylbenzyl acetoacetate (14) 
                                                                 
The reaction  yielded compound 14 (1.11 g, 54%) as a yellow liquid; 1H NMR (400 MHz, 
CDCl3) δ 7.29-7.13 (4H, m, Ar-H), 5.15 (2H, s, OCH2), 3.50 (2H, s, H-3), 2.37 (3H, s, ArMe), 2.25 
(3H, s, H-1); 13C NMR (100 MHz, CDCl3) δ 200.3 (C-2), 166.9 (C-4), 138.5 (C-3’), 135.2 (C-1’), 
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3,4-Dichlorobenzyl acetoacetate (15)145 
 
 
The reaction yielded compound 15 (1.50, 57%) as a pale-yellow liquid.  1H NMR (400 MHz, 
CDCl3) δ 7.46 (1H, d, J = 2.1 Hz, H-2’), 7.43 (1H, d, J = 8.2 Hz, H-5’), 7.20 (1H, dd, J = 8.2, 2.1 
Hz, H-6’), 5.11 (2H, s, OCH2), 3.52 (2H, s, H-3), 2.26 (3H, s, H-1);  
13C NMR (100 MHz, CDCl3) δ 
200.1 (C-2), 166.7 (C-4), 135.5 (C-1’), 132.8 (C-4’), 132.6 (C-3’), 130.7 (C-5’), 130.2 (C-2’), 
127.5 (C-6’), 65.5 (OCH2), 49.9 (C-3), 30.3 (C-1). 
 
2,4-Dichlorobenzyl acetoacetate (16)146 
 
The reaction yielded compound 16 (2.58 g, 99%) as a colourless solid; 1H NMR (400 MHz, 
CDCl3) δ 7.42 (1H, d, J = 8.4 Hz, H-6’), 7.36 (1H, d, J = 2.1  Hz, H-3’), 7.25 (1H, dd, J = 8.4,  2.1 
Hz, H-5’), 5.24 (2H, s, OCH2), 3.53 (2H, s, H-3), 2.27 (3H, s, H-1);  
13C NMR (100 MHz, CDCl3) δ 
200.1 (C-2), 166.6 (C-4), 135.0 (C-1’), 134.5 (C-4’), 131.2 (C-2’), 131.0 (C-6’), 129.5 (C-3’), 
127.3 (C-5’), 63.7 (OCH2), 49.9 (C-3), 30.1 (C-1). 
 
3,4-Dimethylbenzyl acetoacetate (17) 
 
The reaction yielded compound 17 (0.696 g, 32%) as a colourless liquid.  1H NMR (400 MHz, 
CDCl3) δ 7.13 (1H, d, J = 8.0 Hz, H-5’ ), 7.34 (1H, bs, H-2’), 7.09 (1H, dd, J = 8.0, 2.0 Hz, H-6’), 
5.11 (2H, s, OCH2), 3.48 (2H, s, H-3), 2.28-2.26 (6H, m, ArMe), 2.25 (3H, s, H-1); 
13C NMR (100 
MHz, CDCl3) δ 200.5 (C-2), 167.0 (C-4), 137.2 (C-3’), 136.9 (C-4’), 132.6 (C-1’), 129.9 (C-5’), 
129.8 (C-2’), 126.1 (C-6’), 67.3 (OCH2), 50.2 (C-3), 30.2 (C-1), 19.8 (Arme), 19.6 (Arme). 
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2-Pyridylethyl acetoacetate (18)147 
 
The reaction was done using methyl acetoacetate (80.0 mmol) and 2-(2-pyridyl)ethanol 
(10.0 mmol). The reaction  yielded compound 18 (1.47 g, 70%) as a  yellow liquid. 1H NMR 
(400 MHz, CDCl3) δ 8.50 (1H, d, J = 6.0 Hz , H-6’), 7.60-7.56 (1H, m,  H-4’), 7.14 (1H, d, J = 8.0 
Hz, H-3’), 7.11 (1H, m, H-5’), 4.52 (2H, m, OCH2), 3.37 (2H, s, H-3), 3.10 (2H, t, J = 6.8 Hz, 




The reaction yielded compound 19 (1.97 g, 63%) as a  pale-yellow liquid. 1H NMR (400 MHz, 
CDCl3) δ 4.26 (2H, t, J = 5.8 Hz, OCH2), 3.45 (2H, s, H-3), 3.40 (4H, t, J = 5.2 Hz, H-2’), 2.64 (2H, 
t, J = 5.8 Hz, NCH2), 2.43 (4H, t, J = 5.2 Hz, H-3’), 2.27 (3H, s, H-1), 1.45 (9H, s, Met-butyl); 
  13C 
NMR (100 MHz, CDCl3) δ 200.3 (C-2), 166.9 (C-4), 154.7 (NCO), 79.7 (OC-t-butyl), 62.3 
(OCH2), 56.5 (C-2’), 53.7 (NCH2), 50.1 (C-3), 43.6 (C-3’), 30.1 (C-1), 28.4 (Met-butyl). 
 
2-(piperidin-1-yl)ethyl acetoacetate (20)149                                                            
 
The reaction  yielded compound 20 (957 mg, 45%) as a colourless liquid. 1H NMR (400 MHz, 
CDCl3) δ 4.28 (2H, t, J = 6.0 Hz, OCH2), 3.47 (2H, s, H-3), 2.64 (2H, t, J = 6.0 Hz, NCH2), 2.45 
(4H, t, J = 5.4 Hz, H-2’), 2.29 (3H, s, H-1), 1.64-1.59 (4H, m, H-3’), 1.47-1.43 (2H, m, H-4’); 13C 
NMR (100 MHz, CDCl3) δ 200.5 (C-2), 167.0 (C-4), 62.7 (OCH2), 57.2 (NCH2), 54.8 (C-2’), 50.2 
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Representative procedure for synthesis of the 1,4-dihydropyridine analogues: 
Ammonium acetate (1.40 mmol, 5.00 eq), 3,4-dichlorobenzaldehyde (0.280 mmol, 1.00 eq) 
and the relevant acetoacetate (5.60 mmol, 20.0 eq) were dissolved in ethanol (2.00 ml). The 
reaction mixture was microwave irradiated at 60 °C, 250 W until completion (8-26 minutes) 
followed by the removal of ethanol. Water (5.00 mL) was then added to the resultant 
residue, which was extracted using ethyl acetate (3x 15.0 mL), the organic extracts dried 
with MgSO4 and the solvent removed under reduced pressure. Column chromatography was 
performed and the product obtained (solid) recrystallized from DCM/hexane to yield the 
product. 
To the best of our knowledge all the compounds are novel compounds except for 22 and 23 
which were reported by Pedemonte et al.. with no physical data to support the successful 





The reaction yielded compound 21 (84 mg, 88%) as pale-yellow crystals; m.p. 179-180  °C; 
HPLC: 99%; HRMS (EI): m/z 338.0715 [M+H]+, C17H18Cl2NO2 requires 338.0715; 
1H NMR (400 
MHz, CDCl3) δ 7.30 (1H, d, J = 1.6 Hz, H-2’), 7.28 (1H, d, J = 8.4 Hz, H-5’), 7.10 (1H, dd, J = 8.4 
, 2.1, Hz, H-6’), 5.81 (1H, bs, NH), 5.15 (1H, s, H-4), 2.34 (6H, s, Meketone), 2.26 (6H, s, Me); 
13C 
NMR (100 MHz, CDCl3) δ 197.1 (CO), 146.0 (C-2), 143.2 (C-1’), 132.4 (C-3’), 130.5 (C-4’), 
130.3 (C-2’), 129.4 (C-5’), 127.1 (C-6’), 113.5 (C-3), 39.1 (C-4), 30.2 (Meketone), 20.5 (Me); IR. 
vmax/ cm-
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The reaction was performed on a 0.853 mmol scale of aldehyde. The mixture was refluxed 
under N2 yielding compound 22 (242 mg, 66%) as a colourless powder; m.p. 176-177 °C; 
HPLC: 98 %; HRMS (EI): m/z 370.0598 [M+H]+, C17H18Cl2NO4 requires 370.0613; 
1H NMR (400 
MHz, CDCl3) δ 7.31 (1H, d, J = 2.0 Hz, H-2’), 7.28 (1H, d, J = 8.2 Hz, H-5’), 7.11 (1H, dd, J = 8.2, 
2.0 Hz, H-6’), 5.64 (1H, bs, NH), 4.97 (1H, s, H-4), 3.66 (6H, s, OMe), 2.35 (6H, s, Me). 13C 
NMR (100 MHz, CDCl3) δ 167.4 (CO), 147.5 (C-2), 144.4 (C-1’), 131.7 (C-3’), 129.9 (C-4’), 
129.7 (C-2’), 129.5 (C-5’), 127.1 (C-6’), 103.5 (C-3), 50.9 (OMe),  38.8 (C-4), 19.5 (Me); vmax/ 
cm-1 3352 (N-H), 3255 (C-H aromatic ), 2957 (C-H alkane), 1710 (C=O ), 1652 (C=C aromatic), 




The reaction was performed on a 0.332 mmol scale. The reaction yielded compound 23 (126 
mg, 96%) as pale yellow crystals; m.p. 131-133 °C; HPLC: 97 %; HRMS (EI): m/z 398.0923 
[M+H]+, C19H22Cl2NO4 requires 398.0926; 
1H NMR (400 MHz, CDCl3) δ 7.36 (1H, d, J = 2.1 Hz, 
H-2’), 7.27 (1H, d, J = 8.3 Hz, H-5’),  7.15 (1H, dd, J = 8.3 Hz, 2.1 Hz, H-6’), 5.64 (1H, bs, NH), 
4.98 (1H, s, H-4), 4.19 – 4.07 (4H, m, OCH2), 2.37 (6H, s, Me), 1.25 (6H, t, J = 7.2 Hz, Meester);
 
13C NMR (100 MHz, CDCl3) δ 169.1 (CO), 149.0 (C-2), 144.2 (C-1’), 132.2 (C-3’), 130.1 (C-
2’),129.9 (C-4’), 129.7 (C-5’), 127.6 (C-6’), 103.8 (C-3), 59.9 (OCH2), 39.4 (C-4), 19.6 (Me), 
Chapter 5: Experimental Section 
94 | P a g e  
 
14.2 (Meester); vmax/ cm
-1 3353 (N-H), 3254 (C-H aromatic ), 2956 (C-H alkane), 1713 (C=O ), 
1652 (C=C aromatic), 1124 (C-O ester) 
 
Diallyl 4-(3,4-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (24) 
 
The reaction was performed on a 0.853 mmol scale. The mixture was refluxed under N2 
yielding compound 24 (260 mg, 72%) as a colourless powder; m.p. 149-152 °C; HPLC purity: 
97%; HRMS (EI): m/z 422.0925 [M+H]+, C21H22Cl2NO4 requires 422.0926; 
1H NMR (400 MHz, 
CDCl3) δ 7.33 (1H, d, J = 2.2 Hz, H-2’), 7.26 (1H, d, J = 8.3 Hz, H-5’), 7.12 (1H, dd, J = 8.3, 2.1 
Hz, H-6’),  5.92-5.88 (2H, m, CHvinyl) 5.65 (1H, bs, NH), 5.25-5.22 (4H, m, CH2vinyl), 5.01 (1H, s, 
H-4), 4.90-4.88 (4H, m, OCH2) 2.35 (6H, s, Me); 
13C NMR (100 MHz, CDCl3) δ 166.8 (CO), 
147.7 (C-2), 144.6 (C-1’), 132.5 (CHvinyl), 131.8 (C-3’), 130.0 (C-2’), 129.9 (C-4’), 129.7 (C-5’), 
127.6 (C-6’), 117.9 (CH2 vinyl), 103.3 (C-3), 64.8 (OCH2), 39.2 (C-4), 19.7 (Me); vmax/ cm
-1 3317 
(N-H), 3246 (C-H aromatic ), 3105 (C-H alkene), 2952 (C-H alkane), 1695 (C=O ), 1654 (C=C 





The reaction yielded compound 25 (108 mg, 91%) as colourless crystals; m.p. 167-169 °C; 
HRMS (EI): m/z 426.1236 [M+H]+, C21H26Cl2NO4 requires 426.1239;  
1H NMR (400 MHz, 
CDCl3) δ 7.34 (1H, d, J = 2.1 Hz, H-2’), 7.27 (1H, d, J = 8.3 Hz, H-5’), 7.12 (1H, dd, J = 8.3, 2.0 
Hz, H-6’), 5.55 (1H, bs, NH), 4.96 (2H, sep, J = 6.30 Hz, OCH),  4.92 (1H, s, H-4), 2.33 (6H, s, 
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Me), 1.20 (12H, 2xd, J = 6.2 Hz,  Meisopropyl); 
13C NMR (100 MHz, CDCl3) δ 167.7 (CO), 148.1 
(C-2), 143.9 (C-1’), 130.3 (C-3’), 130.1 (C-4’), 129.7 (C-2’), 129.6 (C-5’), 127.7 (C-6’), 103.8 (C-
3), 66.9 (OCH), 39.4 (C-4), 21.8 (Meisopropyl), 19.4 (Me); vmax/ cm
-1 3315 (N-H), 3118 (C-H 





The reaction was performed on a 0.853 mmol scale. The mixture was refluxed under N2 
yielding compound 26 (197 mg, 51%) as yellow crystals; m.p. 149-151 °C; HPLC: 98%; HRMS 
(EI): m/z 454.1552 [M+H]+, C23H30Cl2NO4 requires 454.1552;  
1H NMR (400 MHz, CDCl3) δ 
7.35 (1H, d, J = 2.0 Hz, H-2’), 7.27 (1H, d, J = 8.3 Hz, H-5’), 7.12 (1H, dd, J = 8.3, 2.1 Hz, H-6’), 
5.36 (1H, bs, NH), 4.80 (1H, s, H-4), 2.23 (6H, s, Me), 1.34 (18H, s, Met-butyl);
 13C NMR (100 
MHz, CDCl3) δ 166.6 (CO), 148.4 (C-2), 143.4 (C-1’), 131.7 (C-3’), 130.2 (C-4’), 129.8 (C-2’), 
129.6 (C-5’), 127.7 (C-6’), 103.8 (C-3), 66.9 (OC-t-butyl), 39.4 (C-4), 21.8 (Met-butyl), 19.4 (Me); 
vmax/ cm
-1 3329 (N-H), 3126 (C-H aromatic ), 2977 (C-H alkane), 1701 (C=O ), 1645 (C=C 





The reaction was performed on a 0.568 mmol scale. The reaction mixture was refluxed 
under N2 yielding compound 27 (224 mg, 82%) a yellow solid; m.p. 129-131 °C; HPLC: 95%; 
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HRMS (EI): m/z 478.1540 [M+H]+, C25H30Cl2NO4 requires 478.1552;
1H NMR (400 MHz, CDCl3) 
δ 7.32 (1H, d, J = 2.1 Hz, H-2’), 7.27 (1H, d, J = 8.0 Hz, H-5’), 7.12 (1H, dd, J = 8.0, 2.0 Hz, H-
6’), 5.60 (1H, bs, NH), 5.17-5.14 (2H, m, H-1’’), 4.89 (1H, s, H-4), 2.33 (6H, s, Me), 1.90-1.75 
(8H, m, H-2’’), 1.70-1.60 (8H, m, H-3’’); 13C NMR (100 MHz, CDCl3) δ 166.9 (CO), 147.9 (C-2), 
144.0 (C-1’), 130.3 (C-3’), 130.1 (C-4’), 130.0 (C-6’), 129.8 (C-5’), 127.5 (C-6’), 103.9 (C-3), 





The reaction was performed on a 0.568 mmol scale. The mixture was refluxed under N2 
yielding compound 28 (230 mg, 80%) as a yellow solid; m.p. 145-147°C; HPLC purity: 97%; 
HRMS (EI): m/z 504.1713 [M-H]-, C27H32Cl2NO4 requires 504.1708;  
1H NMR (400 MHz, CDCl3) 
δ 7.32 (1H, d, J = 1.9 Hz, H-2’), 7.26 (1H, d, J = 8.3 Hz, H-5’), 7.13 (1H, dd, J = 8.3, 1.9 Hz, H-
6’), 5.55 (1H, bs, NH), 4.99 (1H, s, H-4), 4.75 (2H, m, H-1’’),  2.34 (6H, s, Me), 1.90-1.76 (8H, 
m, H-2’’), 1.54-1.50 (4H, m, H-4’’), 1.37-1.34 (8H, m, H-3’’); 13C NMR (100 MHz, CDCl3) δ 
166.6 (CO), 148.0 (C-2), 144.0 (C-1’), 131.6 (C-3’), 137.3 (C-4’), 130.2 (C-2’), 129.7(C-5’), 
127.6 (C-6’), 103.9 (C-3), 72.1 (C-1”), 39.4 (C-4), 31.7 (C-2’’), 25.5 (C-4’’), 23.6 (C-3’’), 19.7 
(Me); vmax/ cm
-1 3339 (N-H), 3109 (C-H aromatic ), 2935 (C-H alkane), 1676 (C=O ), 1652 (C=C 
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Dibenzyl- 4-(3,4-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (29) 
 
The reaction mixture was refluxed under N2 yielding compound 29 (138 mg, 96%) as yellow 
crystals; m.p. 117-119 °C; HPLC purity: 95%; HRMS (EI): m/z 522.1241 [M+H]+, 
C29H26Cl2NO4 requires 522.1239; 
1H NMR (400 MHz, CDCl3) δ 7.30,7.20 (10H, m, HAr (benzyl 
group)), 7.20 (1H, d, J = 2.3 Hz, H-2’), 7.14 (1H, d, J = 8.3 Hz, H-5’), 6.97 (1H, dd, J = 8.3, 2.1 
Hz, H-6’), 5.65 (1H, bs, NH), 5.06 (2H, d, JAB = 12.4 Hz, OCH2), 4.96 (2H, d, JAB = 12.4 Hz, 
OCH2), 4.99 (1H, s, H-4), 2.35 (6H, s, Me); 
13C NMR (100 MHz, CDCl3) δ 167.1 (CO), 148.0 (C-
2), 144.9 (C-1’), 136.4 (C-1’’), 132.0 (C-3’), 130.3 (C-2’), 130.0 (C-4’), 129.9 (C-5’), 128.7 (C-
3’’), 128.4 (C-2’’), 128.3 (C-4’’), 127.9 (C-6’), 103.6 (C-3), 66.1 (OCH2), 39.6 (C-4), 20.1 (Me); 
vmax/ cm
-1 3371 (N-H, two broad peaks), 3036 (C-H aromatic ), 2935 (C-H alkane), 1692 
(C=O), 1651 (C=C aromatic), 1097 (C-O ester). 
 
Bis(4-methylbenzyl)-4-(3,4-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarboxylate (30)  
 
The reaction yielded compound 30 (133 mg, 87%) as colourless crystals; m.p. 174-176 °C; 
HPLC purity: 98%; HRMS (EI): m/z 550.1556 [M+H]+, C30H31Cl2NO4 requires 550.1552;
 1H 
NMR (400 MHz, CDCl3) δ 7.39 (4H, s, H-2’’), 7.34 (1H, d, J = 2.1 Hz, H-2’), 7.27 (1H, d, J = 8.3 
Hz, H-5’), 7.23 (4H, s, H-3’’), 7.10 (1H, dd, J = 8.3, 2.1,  Hz, H-6’), 5.72 (1H, bs, NH), 5.15 (2H, 
d, JAB = 12.4 Hz, OCH2), 5.05 (2H, d, JAB = 12.3 Hz, OCH2), 5.09 (1H, s, H-4), 2.48 (6H, s, ArMe), 
2.46 (6H, s, Me); 13C NMR (100 MHz, CDCl3) δ 166.2 (CO), 147.1 (C-2), 143.8 (C-1’), 137.1 (C-
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4’’), 132.6 (C-1’’), 131.1 (C-3’), 131.0 (C-4’), 129.5 (C-2’), 129.1 (C-5’), 128.5 (C-2’’), 127.6 (C-
3’’), 127.1 (C-6’), 102.8 (C-3), 65.2 (OCH2), 39.7 (C-4), 20.6 (ArMe), 19.8 (Me); vmax/ cm
-1 3313 
(N-H, two broad peaks), 3101 (C-H aromatic ), 2947 (C-H alkane), 1685 (C=O ), 1652 (C=C 





The reaction yielded compound 31 (120 mg, 78%) as colourless crystals; m.p. 107-109 °C; 
HPLC purity: 98%; HRMS (EI): m/z 550.1543 [M+H]+, C31H30Cl2NO4 requires 550.1552;
  1H 
NMR (400 MHz, CDCl3) δ  7.25 (1H, d, J = 2.1 Hz, H-2’), 7.19 (2H, t, J = 8.2 Hz, H-5’’), 7.15 (1H, 
d, J = 8.3 Hz, H-5’), 7.10 (2H, d, J = 7.6 Hz, H-2’’), 7.00 (2H, m, H-4’’), 6.98 (2H, m, H-6’’), 6.98-
6.95 (1H, m, H-6’), 5.61 (1H, bs, NH-1), 5.05 (2H,d, JAB = 12.0 Hz, OCH2), 5.00 (2H, d, JAB = 
12.1 Hz, OCH2), 4.97 (1H, s, H-4), 2.35 (6H, s, ArMe); 2.30 (6H, s, Me); 
13C NMR (100 MHz, 
CDCl3) δ 166.8 (CO), 147.8 (C-2), 144.6 (C-1’), 138.1 (C-3’’), 136.2 (C-1’’), 131.8 (C-3’), 130.1 
(C-2’), 130.0 (C-4’), 129.8 (C-5’), 128.7 (C-2’’), 128.6 (C-5’’), 128.4 (C-4’’), 127.2(C-6’), 125.1 
(C-6’’), 103.5 (C-3), 65.9 (OCH2), 39.3 (C-4),  21.3 (ArMe), 19.8 (Me); vmax/ cm
-1 3314 (N-H), 
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The reaction yielded compound 32 (157 mg, 97%) as yellow crystals; m.p. 111-112 °C; HPLC 
purity: 95%; HRMS (EI): m/z 578.1860 [M+H]+, C33H34Cl2NO4 requires 578.1865; 
1H NMR (400 
MHz, CDCl3)  δ 7.23 (1H, d, J = 2.1 Hz, H-2’), 7.14 (1H, d, J = 8.3 Hz, H-5’), 7.06 (2H, d, J = 8.3 
Hz, H-5’’), 6.98(1H, dd, J = 8.3, 2.1 Hz, H-6’), 6.95 (2H, bs, H-6’’), 6.93 (2H, bs, H-2’’), 5.59 (1H, 
bs, NH), 5.02 (2H, d, JAB = 12.5 Hz, OCH2),5.00,4.96 (2H, d, JAB = 12.4 Hz, OCH2), 4.98 (1H, s, 
H-4), 2.34 (6H, s, Me), 2.25 (6H, s, ArMe-3’’), 2.21 (6H, s, ArMe-4’’); 
13C NMR (100 MHz, CDCl3) 
δ 166.9 (CO), 147.8 (C-2), 144.4 (C-1’), 136.6 (C-3’’), 136.3 (C-4’’), 133.7 (C-1’’), 131.7 (C-2’) 
130.1 (C-5’), 129.9 (C-3’), 129.7 (C-5’’), 129.6 (C-4’), 129.4 (C-2’’), 127.8 (C-6’), 125.6 (C-6’’), 
103.5 (C-3), 65.8 (OCH2), 39.3 (C-4), 19.8 (Me), 19.6 (ArMe-3’’), 19.4 (ArMe-4’’);vmax/cm
-1  3323 






The reaction yielded compound 33 (146 mg, 89%) as colourless crystals; m.p.  176-178 °C; 
HPLC purity: 97%; HRMS (EI): m/z 590.0452, [M+H]+, C29H24Cl4NO4 requires 590.0459; 
1H 
NMR (400 MHz, CDCl3) δ  7.28 (4H, d, J = 6.5, H-3’’), 7.18,7.16 (1H, d, J = 8.2 Hz, H-5’), 7.17 
(1H, d, J = 2.0 Hz, H-2’), 7.12 (4H, d, J = 6.6, H-2’’), 6.96 (1H, dd, J = 8.2, 2.0 Hz, H-6’), 5.65 
(1H, bs, NH), 5.07, 4.94 (2H, d, JAB = 12.5 Hz, OCH2),4.97 (2H, d, JAB = 12.5 Hz, OCH2),  4.89 
(1H, s, H-4), 2.34 (6H, s, Me); 13C NMR (100 MHz, CDCl3) δ 166.6 (C-O), 147.6 (C-2), 144.8 (C-
1’), 134.7(C-1’’134.0 (C-4’’), 131.8 (C-3’), 130.1 (C-4’), 130.0 (C-2’), 129.9(C-5’), 129.5 (C-3’’), 
128.7 (C-2’’), 127.6 (C-6’), 103.9 (C-3), 65.1 (OCH2), 39.4 (C-4), 19.8 (Me); vmax/ cm
-1 3316 (N-
H, two broad peaks), 3105 (C-H aromatic ), 2949 (C-H alkane), 1685 (C=O ), 1652 (C=C 
aromatic), 1088 (C-O ester). 
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The reaction yielded compound 34 (162 mg, 96%) as colourless crystals; m.p.  142-144 °C; 
HPLC purity: 98%; HRMS (EI): m/z 590.0433, [M+H]+, C29H24Cl4NO4 requires 590.0459
1H NMR 
(400 MHz, CDCl3) δ 7.25 (2H, d, J = 1.8 Hz, H-6’’), 7.24,7.18 (1H, d, J = 8.2 Hz, H-5’), 7.22 (2H, 
d, J = 1.9 Hz, H-4’’), 7.20 (1H, d, J = 2.4 Hz, H-2’), 7.16 (2H, bs, H-2’’), 7.05 (2H, d, J = 7.6 Hz, 
H-5’’) 6.96 (1H, dd, J = 8.2, 2.0 Hz, H-6’), 5.69 (1H, bs, NH), 5.11 (2H, d, JAB = 12.0 Hz, 
OCH2),5.01 (2H, d, JAB = 12.0 Hz, OCH2), 4.97 (1H, s, H-4), 2.35 (6H, s, Me); 
13C NMR (100 
MHz, CDCl3) δ 166.5 (CO), 147.5 (C-2), 145.0 (C-1’), 138.3 (C-1’’), 134.4 (C-3’’), 132.2 (C-3’), 
130.3 (C-4’), 129.9 (C-2’), 129.8(C-5’), 129.7 (C-4’’), 128.2(C-6’’), 128.0 (C-2’’), 127.6 (C-6’), 
126.0 (C-5’’), 103.2 (C-3), 65.0 (OCH2), 39.2 (C-4), 19.8 (Me); vmax/ cm
-1 3346 (N-H), 3107 (C-H 







The reaction yielded compound 35 (129 mg, 83%) as yellow crystals; m.p.  122-123 °C; HPLC 
purity: 96%; HRMS (EI): m/z 590.0434, [M+H]+, C29H24Cl4NO4 requires 590.0459; 
1H NMR 
(400 MHz, CDCl3) δ 7.35 (2H, d, J = 8.0 Hz, H-3’’), 7.27-7.23 (2H, m, H-6’’), 7.21 (1H, d, J = 2.0 
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Hz, H-2’), 7.17 (2H, t, J = 2.4 Hz, H-4’’), 7.16 (2H, d, J = 1.1 Hz, H-5’’), 7.12 (1H, d, J = 8.3 Hz, 
H-5’) 6.99 (1H, dd, J = 8.2, 2.2 Hz, H-6’),  5.67 (1H, bs, NH), 5.18 (2H, d, JAB = 12.9 Hz, H-13), 
5.05(2H, d, JAB = 12.8 Hz, OCH2), 5.0 (1H, s, H-4), 2.35 (6H, s, H-5); 
13C NMR (100 MHz, CDCl3) 
δ 166.6 (CO), 147.7 (C-2), 144.9 (C-1’), 133.9(C-1’’), 133.7 (C-3’), 131.8 (C-4’), 130.1 (C-4’’), 
130.0 (C-5’), 129.8 (C-2’), 129.5(C-6’’), 129.3 (C-3’’), 127.6 (C-6’), 126.8 (C-5’’), 103.4 (C-3), 
63.2 (OCH2), 39.2 (C-4), 19.8 (Me); vmax/ cm
-1  3365 (N-H), 3066 (C-H aromatic ), 2951 (C-H 





The reaction yielded compound 36 (139 mg, 73%) as colourless crystals; m.p.  178-179 °C; 
HPLC purity: 95%; HRMS (EI): m/z 677.9428, [M+H]+, C29H24Cl2NO4Br2 requires 677.9449;
1H 
NMR (400 MHz, CDCl3) δ 7.28 (4H, d, J = 6.4 Hz, H-3’’), 7.19,7.16 (1H, d, J = 8.6 Hz, H-5’), 7.17 
(1H, d, J = 2.2 Hz, H-2’), 7.06 (4H, d, J = 6.4 Hz, 2’’), 6.96 (1H, dd, J = 8.3, 2.1 Hz, H-6’),  5.65 
(1H, bs, NH), 5.07 (2H, d, JAB = 12.6 Hz, OCH2),4.97 (2H, d, JAB = 12.6 Hz, OCH2), 4.93 (1H, s, H-
4), 2.34 (6H, s, Me); 13C NMR (100 MHz, CDCl3) δ 166.6 (CO), 147.6 (C-2), 144.8 (C-1’), 
135.2(C-1’’), 131.8 (C-3’), 131.7 (C-3’’), 130.2 (C-4’), 130.1 (C-2’), 129.9(C-5’), 129.8 (C-2’’), 
127.5 (C-6’), 122.5 (C-4’’), 103.4 (C-3), 65.1 (OCH2), 39.3 (C-4), 19.8 (Me);  vmax/ cm
-1 3317 (N-
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The reaction was performed on a 0.568 mmol scale. The reaction yielded compound 37 (231 
mg, 62%) as colourless crystals; m.p.  167-169 °C; HPLC: 95%; HRMS (EI): m/z 655.9504, [M-
H]-, C29H20Cl6NO4 requires 655.9523; 
1H NMR (400 MHz, CDCl3) δ 7.30 (2H, d, J = 8.3 Hz, H-
5’’), 7.19 (1H, d, J = 2.1 Hz, H-2’), 7.17 (2H, d, J = 2.1 Hz, H-2’’), 7.14 (1H, d, J = 10.1 Hz, H-5’), 
6.94 (2H, dd, J = 10.3, 2.1 Hz, H-6’), 6.91 (2H, dd, J = 8.2, 2.1 Hz, H-6’’), 5.65 (1H, bs, NH), 
5.08 (2H, d, JAB = 12.8 Hz, OCH2), 4.92 (2H, d, JAB = 12.8 Hz, OCH2), 4.87 (1H, s, H-4), 2.24 (6H, 
s, Me); 13C NMR (100 MHz, CDCl3) δ 166.4 (CO), 147.4 (C-2), 145.1 (C-1’), 136.5 (C-1’’), 132.7 
(C-3’’), 132.1 (C-4’’) 132.0 (C-3’), 130.5 (C-5’’), 130.4 (C-4’), 130.0 (C-2’), 129.9 (C-5’), 129.8 
(C-2’’), 127.5 (C-6’), 127.2 (C-6’’), 103.0 (C-3), 64.5 (OCH2), 39.2 (C-4), 19.8 (Me);  
vmax/cm
-1 3350 (N-H), 3076 (C-H aromatic ), 2950 (C-H alkane), 1699 (C=O ), 1651 (C=C 





The reaction was performed on a 0.568 mmol scale. The reaction yielded compound 38 (231 
mg, 62%) as colourless crystals; m.p.  162-164 °C; HPLC: 99%; HRMS (EI): m/z 657.9674, [M-
H]-, C29H22Cl6NO4 requires 657.9680; 
1H NMR (400 MHz, CDCl3) δ 7.39 (2H, d, J = 2.8 Hz, H-
3’’), 7.18 (1H, d, J = 2.0 Hz, H-2’), 7.16 (1H, d, J = 8.3 Hz, H-5’), 7.14 (2H, dd, J = 9.0, 2.8 Hz, H-
5’’), 7.09 (2H, d, J = 9.0 Hz, H-6’’), 6.97 (1H, dd, J = 8.3, 2.0 Hz, H-6’), 5.70 (1H, bs, NH), 5.15 
Chapter 5: Experimental Section 
103 | P a g e  
 
(2H, d, JAB = 12.8 Hz, OCH2), 5.04 (2H, d, JAB = 12.6 Hz, OCH2), 4.93 (1H, s, H-4), 2.35 (6H, s, 
Me); 13C NMR (100 MHz, CDCl3) δ 166.4 (CO), 147.4 (C-2), 145.1 (C-1’), 134.7 (C-4’’), 134.5 
(C-2’’), 132.5 (C-1’’), 131.8 (C-3’), 131.0 (C-3’’), 130.2 (C-4’), 130.0 (C-6’’), 129.9 (C-2’), 129.4 
(C-5’), 127.5 (C-6’), 127.1 (C-5’’), 103.3 (C-3), 62.5 (OCH2), 39.2 (C-4), 19.8 (Me);  
vmax/ cm
-1 3350 (N-H), 3076 (C-H aromatic ), 2950 (C-H alkane), 1699 (C=O ), 1651 (C=C 
aromatic), 1095 (C-O ester). 
 
Dimethyl 4-(3,4-dichlorophenyl)-2,6-diethyl-1,4-dihydropyridine-3,5-dicarboxylate (39) 
 
The reaction was performed on a 0.568 mmol scale. The reaction yielded compound 39 (210 
mg, 93%) as colourless crystals; m.p.  147-149 °C; HPLC purity: 96%; HRMS (EI): m/z 
398.0920, [M+H]+, C19H22Cl2NO4 requires 398.0926; 
1H NMR (400 MHz, CDCl3) δ 7.31 (1H, d, 
J = 2.1 Hz, H-2’), 7.27 (1H, d, J = 8.2 Hz, H-5’), 7.11 (1H, dd, J = 8.4 Hz, 2.2 Hz, H-6’), 5.74 (1H, 
bs, NH), 4.97 (1H, s, H-4), 3.67 (6H, s,  OMe), 2.64-2.56 (4H, m, CH2),  1.25 (6H, t, J = 7.5 Hz, 
Me); 13C NMR (100 MHz, CDCl3) δ 167.1 (CO), 150.3 (C-2), 147.7 (C-1’), 131.9 (C-3’), 129.9 (C-
2’), 129.7 (C-4’), 129.6 (C-5’),  127.1 (C-6’), 102.3 (C-3), 51.1 (OMe),  38.8 (C-4), 26.0 (CH2), 
12.7 (Me); vmax/ cm
-1 3335 (N-H), 3238 (C-H aromatic ), 2986-2880 (C-H alkane), 1701 (C=O ), 




The reaction was performed on a 0.568 mmol scale. The reaction yielded compound 40 (239 
mg, 98%) as colourless crystals; m.p.  119-121 °C; HPLC: 99%; HRMS (EI): m/z 426.1243, 
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[M+H]+, C21H26Cl2NO4 requires 426.1239;  
1H NMR (400 MHz, CDCl3) δ 7.34 (1H, d, J = 2.1 Hz, 
H-2’), 7.27 (1H, d, J = 8.3 Hz, H-5’), 7.12 (1H, dd, J = 8.3 Hz, 2.1 Hz, H-6’), 5.66 (1H, bs, NH), 
4.95-4.60 (1H, s, H-4), 4.10-3.86 (4H, m,  OCH2), 2.70-2.30 (4H, m, CH2), 1.25 (6H, t, J = 7.1,  
Me ester), 1.20 (6H, t, J = 7.5 Hz, Me);
 13C NMR (100 MHz, CDCl3) δ 166.8 (CO), 149.9 (C-2), 
148.1 (C-1’), 130.1 (C-4’), 130.0 (C-2’), 129.9 (C-4’), 129.8 (C-5’), 127.4 (C-6’), 102.6 (C-3), 
59.9 (OCH2), 39.4 (C-4), 26.1 (CH2), 14.2 (Me ester), 12.7 (Me); vmax/ cm
-1 3350 (N-H), 3240 (C-





Method: tert-Butyl acetoacete (0.568 mmol, 2.00 eq)   and 3,4-dichlorobenzaldehyde (0.284 
mmol, 1.00 eq) in ethanol (1.00 mL) were added to a microwave reaction vial, a few drops of 
triethylamine were then added and the mixture was microwave irradiated for a minute at 
60 °C.  Ethyl-3-aminocrotonate (0.568 mmol, 2.00 eq) was   added followed by a few drops 
of glacial acetic acid and the resultant mixture was further irradiated at 60 °C,  for 15 
minutes. The general extraction and purification for 1,4-dihydropyridines was then followed 
to yield compound 41  (43.0 mg, 36%) as an orange oil; HPLC: 95%; HRMS (EI): m/z 
426.1223, [M+H]+, C21H26Cl2NO4 requires 426.1239;  
1H NMR (400 MHz, CDCl3) δ 7.34 (1H, d, 
J = 2.1 Hz, H-2’), 7.27 (1H, d, J = 8.3 Hz, H-5’), 7.12 (1H, dd, J = 8.3 Hz, 2.1 Hz, H-6’), 5.52 (1H, 
bs, NH-1), 4.90 (1H, s, H-4), 4.10 (2H, q, J = 7.2 Hz,   OCH2), 2.32(3H, s, Me-2), 2.30 (3H, s, 
Me-6), 1.40 (9H, s, Met-butyl), 1.22 (3H, t, J = 7.1 Hz, Me ester); 
13C NMR (100 MHz, CDCl3) δ 
167.2 (COethyl) 166.5 (COt-butyl), 148.1 (C-2), 144.3 (C-1’), 143.1 (C-6), 131.7 (C-3’), 130.1 (C-
2’), 129.7 (C-4’), 129.6 (C-5’), 127.5 (C-6’), 105.0 (C-5), 103.8 (C-3), 80.1 (OC-t-butyl),  59.8 
(OCH2), 39.7 (C-4), 28.3 (Met-butyl), 19.6 (Me-2), 19.5 (Me-6), 14.2 (Me ester) . 
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Diethyl 4-(3,4-dichlorophenyl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate (42) 
 
Method: Sodium hydride (2.51 mmol, 2.00 eq) was dissolved in anhydrous THF (2.00 mL) 
and the mixture cooled to  0 °C under N2 atmoshpere. A solution of compound 23 (0.752 
mmol, 1.00 eq) in THF (2.00 mL) was then added slowly to the cooled mixture for a period of 
10 minutes and the resultant mixture warmed up to room temperature and left stiring for 
further 20 minutes before being cooled to 0 °C again. Dimethyl sulfate (0.903 mmol, 1.20 
eq) was then added drop-wise for another 10 minutes and the mixture stirred to room 
temperature for further 5 minutes.  Removal of THF was then done under reduced pressure 
and the resultant crude mixture quenched with sodium bicarbonate (5.00 mL) and washed 
with brine (10.0 mL). Ethyl acetate (3x 15.0 mL) was used to extract the organic extracts 
which were then dried with MgSO4 and the solvent removed on the rotary-evaporator to 
yield  crude product that was purified using column chromatography (solvent system 
hexane/ethyl acetate (3:1)) to yield compound 42 (304 mg, 98%)  as a yellow solid; m.p. 74-
76 °C; HPLC: 97%; HRMS (EI): m/z 412.1080, [M+H]+, C20H24Cl2NO4 requires 412.1082;  
1H 
NMR (400 MHz, CDCl3) δ 7.25 (1H, d, J = 8.4 Hz, H-5’), 7.23 (1H, d, J = 2.4 Hz, H-2’), 7.03 (1H, 
dd, J = 8.3 Hz, 2.2 Hz, H-6’), 5.01 (1H, s, H-4), 4.18-4.12 (4H, m, OCH2), 3.18 (3H, s, NMe), 
2.48 (6H, s, Me), 1.27 (6H, t, J = 7.1 Hz, Me ester).
 13C NMR (100 MHz, CDCl3) δ 167.3 (CO), 
149.5 (C-2), 146.3 (C-1’), 131.7 (C-3’),  129.8 (C-2’), 129.7 (C-4’), 129.1 (C-5’), 126.4 (C-6’), 
105.5 (C-3), 59.9(OCH2), 37.8 (C-4), 33.9 (NHMe), 16.3 (Me), 14.1 (Me ester). vmax/ cm
-1 3063 






Chapter 5: Experimental Section 





The reaction yielded compound 43 (136 mg, 62%) as a yellow solid; m.p. 62-64 °C; HPLC: 
97% HRMS (EI): m/z 766.3346 [M+H+], C37H54Cl2N5O8 requires 776.3349; 
1H NMR (400 MHz, 
CDCl3) δ  7.34 (1H, d, J = 2.0 Hz, H-2’), 7.27 (1H, d, J = 8.1 Hz, H-5’), 7.15 (1H, dd, J = 8.2 Hz, 
2.0 Hz, H-6’), 5.69 (1H, s, NH-1), 4.95 (1H, s, H-4), 4.18-3.98 (4H, m,  OCH2), 3.38 (8H, t, J = 
5.20 Hz, H-3’’), 2.58 (4H, td, J = 12.0, 5.8 Hz, NCH2), 2.39 (8H, t, J = 5.20 Hz, H-2’’), 2.35 (6H, 
s, Me), 1.46 (18H, s, Met-butyl).
  13C NMR (100 MHz, CDCl3) δ 166.9 (CO),154.8 (NCO),  147.8 
(C-2), 144.63 (C-1’),  131.7 (C-3’), 130.0 (C-4’), 129.9 (C-2’),129.8 (C-5’), 127.5 (C-6’), 103.5 
(C-3), 79.7 (OC-t-butyl), 61.2 (CH2), 56.5 (NCH2), 53.7 (C-3’’), 43.6 (C-2’’), 39.1 (C-4), 28.5 
(Met-butyl), 19.7 (Me). 
 
Bis(2-(piperidin-1-yl)ethyl)-4-(3,4-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarboxylate (44)  
 
The reaction was performed on a 0.568 mmol scale. The reaction yielded compound 44 (267 
mg, 83%) as an orange oil; HPLC: 99%; HRMS (EI): m/z 564.2393, [M+H]+, 
C21H26Cl2N3O4 requires 564.2396;  
1H NMR (400 MHz, CDCl3) δ  7.34 (1H, d, J = 2.0 Hz, H-2’), 
7.25 (1H, d, J = 8.3 Hz, H-5’), 7.17 (1H, dd, J = 8.3 Hz, 2.1 Hz, H-6’), 5.63 (1H, s, NH-1), 4.96 
(1H, s, H-4), 4.20 (4H, q, J = 7.2 Hz,  OCH2), 2.59 (4H, t, J = 6.0 Hz, NCH2), 2.40 (8H, t, J = 5.4 
Hz, H-2’’), 2.35 (6H, s, Me), 1.58 (8H, m, H-3’’), 1.50-1.43 (4H, m, H-4’’); 13C NMR (100 MHz, 
CDCl3) δ 167.0 (CO), 147.7 (C-2), 144.6 (C-1’),  131.7 (C-3’), 130.0 (C-4’), 129.9 (C-2’),129.8 
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(C-5’), 127.6 (C-6’), 103.3 (C-3), 61.7 (CH2), 57.3 (C-2’’), 54.7 (NCH2), 39.1 (C-4), 25.9 (C-3’’), 
24.1 (C-4’’), 19.7 (Me).  
 
General Procedure for the syntheses of the 1,4-pyridine derivatives: 
 A suspension of a 1,4-dihydropyridine (0.502 mmol, 1.00 eq), oxone® (0.753 mmol, 1.50 
eq), wet silica (50 % w/w) (0.753 mmol, 1.50 eq) and NaNO2 (1.51 mmol, 3.00 eq) in DCM 
(2.00 mL)  was taken into a round bottom flask and  stirred at room temperature for the  
required time (60-120 minutes). The mixture was then filtered and the residue washed with 
DCM (3x 10 mL) followed by filtrate being dried with MgSO4. The solvent was then 
evaporated under reduced pressure and crude mixture purified by column chromatography 
followed by recrystallization from DCM/ hexane to yield the required product.   
 
Diethyl 4-(3,4-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate (45)  
 
The reaction yielded compound 45 (139 mg, 70%) as  colourless crystals; m.p. 62-64 °C; 1H 
NMR (400 MHz, CDCl3) δ 7.45 (1H, d, J = 8.3 Hz, H-5’), 7.38 (1H, d, J = 2.0 Hz, H-2’), 7.10 (1H, 
dd, J = 8.3 Hz, 2.0 Hz, H-6’), 4.08 (4H, q, J = 9.4 Hz, OCH2), 2.60 (6H, s, , Me), 1.05 (6H, t, J = 
7.2 Hz, ester Me); 13C NMR (100 MHz, CDCl3) δ 167.4 (CO), 155.8 (C-2), 143.5 (C-4), 136.3 (C-
1’), 133.0 (C-4’), 132.5 (C-3’), 130.2 (C-5’), 130.1 (C-5’), 127.7 (C-6’), 126.6 (C-3), 61.6 (OCH2), 
23.0 (Me), 13.8 (ester Me). vmax/cm
-1 3059 (C-H aromatic ), 2959 (C-H alkane), 1726 (C=O ), 
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The reaction yielded compound 46 (142 mg, 66%) as  yellow crystals; m.p. 71-73 °C; HPLC: 
98% HRMS (EI): m/z 430.1031 [M+H+], C20H20F3ClNO4 requires 430.1033; 
 1H NMR (400 MHz, 
CDCl3) δ 7.63 (1H. d, J = 2.0 Hz, H-2’), 7.53 (1H, d, J = 8.4 Hz, H-5’),  7.38 (1H, dd, J = 8.4, 2.0 
Hz, H-6’), 4.06 (4H, q, J = 7.1 Hz, OCH2), 2.38 (6H,s, Me), 1.22 (6H, t, J = 7.2 Hz, Me ester);
 13C 
NMR (100 MHz, CDCl3) δ 167.4 (CO), 156.2 (C-2), 143.5 (C-4), 135.6 (C-1’), 132.9 (C-4’), 132.8 
(C-2’), 131.4 (C-5’), 128.5 (q, JCF = 30 Hz, C-3’),127.6 (C-6’), 126.7 (C-3), 122.0 (q, JCF = 200 Hz 
CF3), 61.8 (OCH2), 23.5 (Me), 13.8 (Me ester). vmax/ cm
-1  3063 (C-H aromatic ), 2965 (C-H 
alkane), 1730 (C=O ), 1566 (C=C aromatic), 1547 (C=N), 1102 (C-O ester). 
 
Diethyl 2,6-dimethyl-4-(4-nitrophenyl)pyridine-3,5-dicarboxylate (47) 
 
The reaction yielded compound 47 (129 mg, 69%) as yellow crystals; m.p. 114-115 °C; HPLC: 
97%;  1H NMR (400 MHz, CDCl3) δ= 8.24 (2H, d, J = 8.8 Hz,  H-3’), 7.50 (2H, d, J = 8.8 Hz, H-2’), 
4.04 (4H, q, J = 7.2 Hz, OCH2), 2.60 (6H, s, Me), 0.98 (6H, t, J = 7.2 Hz, Me ester); 
13C NMR (100 
MHz, CDCl3) δ 167.1 (CO), 156.2 (C-2), 145.0 (C-4), 144.0 (C-4’), 143.3 (C-1’), 129.4 (C-2’), 
126.2 (C-3), 123.3 (C-3’), 61.5 (OCH2), 23.1 (Me), 13.7 (Me ester). vmax/ cm
-1  3067 (C-H 
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Bis(2-chlorobenzyl) 4-(3,4-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate (48) 
 
The reaction was performed on a 0.109 mmol scale. The reaction yielded compound 48 (40 
mg, 63%) as yellow crystals; m.p. 123-125 °C; HPLC: 96% HRMS (EI): m/z 588.0306 [M+H+], 
C29H22Cl4NO4 requires 588.0303;  
1H NMR (400 MHz, CDCl3) δ 7.31 (2H, d, J = 8.0 Hz, H-3’’), 
7.29 (1H, d, J = 2.1 Hz, H-2’), 7.22 (2H, t, J = 9.2 Hz, H-5’’), 7.16 (2H, d, J = 7.1 Hz, H-6’’), 7.09 
(2H, d, J = 7.5,  H-4’’), 7.02 (1H, d, J = 8.3 Hz, H-5’), 6.89 (1H, dd, J = 8.3, 2.1 Hz, H-6’), 5.15 
(4H, s, OCH2), 2.60 (6H, s, Me); 
13C NMR (100 MHz, CDCl3) δ 167.1 (CO), 156.1 (C-2), 146.3 
(C-4), 135.6 (C-1’), 134.3 (C-1’’), 132.6 (C-4’), 132.0 (C-3’), 131.0 (C-3’’), 130.1 (C-6’’), 130.0 
(C-2’), 129.8 (C-5’), 129.7 (C-2’’), 129.6 (C-4’’), 126.9 (C-6’), 126.2 (C-5’’), 64.6 (OCH2), 23.0 
(Me); vmax/ cm
-1  3068 (C-H aromatic ), 2956 (C-H alkane), 1729 (C=O ), 1680 (C=C aromatic), 
1548 (C=N), 1101 (C-O ester). 
 
Dibenzyl 4-(3,4-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate (49) 
 
The reaction was performed as for the previously described general procedure for syntheses 
of 1,4-dihydropyrines, however, the reaction yielded compound 49 (140 mg, 95%) as 
colourless powder; m.p. 106-108 °C; HPLC: 95% HRMS (EI): m/z 520.1087 [M+H+], 
C29H24Cl2NO4 requires 520.1082;  
1H NMR (400 MHz, CDCl3) δ  7.30 (6H, m, H-3’’ and H-4’’), 
7.18 (1H, d, J = 2.2 Hz, H-2’), 7.06 (1H, d, J = 8.4 Hz, H-5’), 7.05, 7.03 ( 4H, m, H-2’’), 6.87 (1H, 
dd, J = 8.4, 2.2 Hz, H-6’), 5.01 (4H, s, OCH2), 2.55 (6H, s, Me); 
13C NMR (100 MHz, CDCl3) δ 
167.3 (CO), 156.1 (C-2), 143.5 (C-4), 137.8 (C-1’), 134.3 (C-1’’), 133.0 (C-4’), 132.5 (C-3’), 
130.1 (C-2’), 129.8 (C-5’), 128.7 (C-3’’), 128.6 (C-4’’), 128.5 (C-2’’), 127.3 (C-6’), 126.3 (C-3), 
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67.6 (OCH2), 23.0 (Me); vmax/ cm
-1  3061 (C-H aromatic ), 2964 (C-H alkane), 1730 (C=O ), 
1563 (C=C aromatic), 1550 (C=N), 1107 (C-O ester). 
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5.2 β-haematin inhibition assay method 
The β-haematin inhibition assay was measured using the method described by Carter et. 
al.99 Modifications were done for manual liquid delivery.  A 20 ml stock solution containing 
water/acetone/NP-40 (305.5 µM)/DMSO 35%/35%/20%/10% (v/v) was prepared. Using a 
multichannel pipette, 100µM of the detergent solution was added to each well (columns 1-
11) in the plate. The compounds were dissolved in DMSO to give final concentration of 20 
mM thereafter followed by delivery of the compound to the wells (column 12). A serial 
dilution of the solution using a multichannel pipette to give final concentrations of 0 -1000 
µM was done. A solution of 25 mM haematin was prepared by dissolving 8 mg of haemin in 
0.5 mL of dimethyl sulfoxide (DMSO) and sonicated for complete dissolution. For a final 
222.2 µM buffered solution, 178.8 µM of the 25 mM haematin solution was added to 20 mL 
solution of 1 M sodium acetate buffer (pH 4.9) prepared by dissolving sodium acetate in H2O 
with 2.4 ml acetic acid to make a 50 ml solution. Addition of buffered solution to the wells 
gave final haematin and acetate buffer concentrations of 100 µM and 1 M respectively, 
followed by incubation of plate at 37 °C in a water bath for 5 hours. The β-haematin 
inhibition assay analysis was done using the colorimetric pyridine-ferrichrome method 
developed by Ncokazi and Egan.123 A solution of 50% (v/v) pyridine, 20 % (v/v) acetone, 30% 
(v/v) H2O and 0.2 M HEPES buffer (pH 7.4) was prepared and 32 µL added to each of the 
well plate to give a final pyridine concentration of 5% (v/v). Acetone (60 µL) was then added 
to each well. To determine the drug response against β-haematin formation, absorbance of 
the pyridine-haem complex in the plate wells was measured at 405 nm using a SpectaMax 
plate reader. The data were then fitted to a sigmoidal dose-response curve using the 
GraphPad Prism v3.02 programme and the IC50 (amount of drug needed to inhibit β-
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5.3 The parasite growth inhibition assay. 
 The antiplasmodium activity was measured using a method described previously. 125A 
20mg/ml stock solution of test sample was prepared by dissolving each analogue in 100% 
DMSO followed by sonication of the mixture. Thereafter delivery of the compound to the 
well plate containing the P. falciparum infected RBC was carried out. A serial dilution using a 
multichannel pipette from 100 µg/nL to final concentration of 0.2 µg/nL was then done. The 
test samples were tested against P. falciparum infected RBC and quantitative assessment of 




                            
Assuming pHv = 5.0 
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